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Edited by Viktor KorolchukAbstract
Autophagy is an intracellular degradation process that is essential for cellular survival, tissue homeostasis,
and human health. The housekeeping functions of autophagy in mediating the clearance of aggregation-
prone proteins and damaged organelles are vital for post-mitotic neurons. Improper functioning of this process
contributes to the pathology of myriad human diseases, including neurodegeneration. Impairment in
autophagy has been reported in several neurodegenerative diseases where pharmacological induction of
autophagy has therapeutic benefits in cellular and transgenic animal models. However, emerging studies
suggest that the efficacy of autophagy inducers, as well as the nature of the autophagy defects, may be
context-dependent, and therefore, studies in disease-relevant experimental systems may provide more
insights for clinical translation to patients. With the advancements in human stem cell technology, it is now
possible to establish disease-affected cellular platforms from patients for investigating disease mechanisms
and identifying candidate drugs in the appropriate cell types, such as neurons that are otherwise not
accessible. Towards this, patient-derived human induced pluripotent stem cells (hiPSCs) have demonstrated
considerable promise in constituting a platform for effective disease modeling and drug discovery. Multiple
studies have utilized hiPSC models of neurodegenerative diseases to study autophagy and evaluate the
therapeutic efficacy of autophagy inducers in neuronal cells. This review provides an overview of the
regulation of autophagy, generation of hiPSCs via cellular reprogramming, and neuronal differentiation. It
outlines the findings in various neurodegenerative disorders where autophagy has been studied using hiPSC
models.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Mechanisms of Autophagy
Macroautophagy (referred herein as autophagy) is
a highly conserved catabolic pathway, which deli-
vers undesirable cytoplasmic materials to the lyso-
somes for their degradation. It plays a constitutiveuthors. Published by Elsevier Ltd. This
es/by/4.0/).role in the quality control of intracellular macromo-
lecules and organelles, thus imperative for the
maintenance of cellular homeostasis that is vital for
human health [1,2]. Though, it can be triggered
under various environmental cues, such as stress
conditions like starvation, hypoxia, and oxidativeJournal of Molecular Biology (2020) 432, 2754e2798
is an open access article under the CC BY license (http://
2755stress, or pathogenic stimulation like viral and
bacterial infection [3,4]. Over the last two decades,
numerous studies have shown that autophagy
predominantly acts as a cellular survival pathway.
It is implicated in myriad human physiology, includ-
ing development and immunity, whereas its mal-
function contributes to the pathology of diverse
human diseases, including neurodegeneration
[5e7]. In recent years, a homeostatic role of
autophagy has been attributed to the control of
embryonic and adult stem cell functions by acting as
a critical quality control mechanism [8,9].
The initiation of the autophagy process in mam-
malian cells involves the genesis of the phagophore,
which is an isolation membrane structure that is
derived from the endoplasmic reticulum (ER)-ema-Fig. 1. Mechanism of the autophagy process. Autophagy e
fusion events through which the autophagic cargo is degraded.
the phagophore assembly site (PAS). The autophagic mach
enables the expansion of the phagophore to form autophagoso
during which specific autophagy receptors mediate selective ca
late endosomes to form amphisomes and then with the lys
lysosomes forming autolysosomes. These vesicle fusion ev
various SNAREs, tethering proteins, and Rab7. The autophagi
lysosomal acid hydrolases.nating membrane domains termed as “omegasome”
and/or from other sources like trans-Golgi, recycling
endosomes, plasma membrane and mitochondria
[10,11]. The phagophore expands to engulf intracel-
lular autophagic cargo that comprises unwanted
macromolecules like protein aggregates or damaged
organelles like mitochondria, thereby sequestering
the cargo in a double-membrane structure called the
autophagosome. The cargo-loaded autophagosome
then matures through fusion with the lysosome to
form autolysosome, thereby promoting the degrada-
tion of the autophagosomal content by the lysosomal
digestive enzymes [12]. Autophagosome maturation
is generally a multistep process wherein the autop-
hagosome initially fuses with the late endosome to
form a hybrid organelle called amphisome, whichncompasses multiple vesicular compartments and vesicle
This process initiates with the formation of phagophores at
inery involving several autophagy-related (ATG) proteins
mes. Autophagic cargo is engulfed in the autophagosomes
rgo recognition. The autophagosomes either fuse with the
osomes to form autolysosomes or directly fuse with the
ents during autophagosome maturation are mediated by
c cargo is eventually degraded in the autolysosomes by the
2756acts as a sink for autophagic and endocytic cargo
materials for delivery to the lysosomes; however, the
autophagosome can also directly fuse with the
lysosomes [13,14] (Fig. 1). The dynamic turnover
of autophagosomes (autophagosome flux) and
autophagic cargo (autophagic cargo flux) is collec-
tively defined as autophagic flux.
Autophagy machinery
The quantum leap in the explication of the
molecular machinery controlling autophagy came
from the genetic studies in yeasts by Ohsumi and
colleagues during the 1990s, in which autophagy-
related (Atg) genes were identified [15]. Since then,
numerous studies have elucidated that this dedi-
cated cohort of ATG proteins assembles into
functional complexes that are activated and
recruited to specific membrane structures to initiate
the autophagy process [16,17] (Fig. 1). The apical
step in the initiation process involves the activation of
the ULK1 (unc-51-like kinase-1) complex [18], which
consists of the serine/threonine-protein kinase ULK1
(mammalian orthologue of yeast Atg1) and three
scaffold proteins that include FIP200 (focal adhesion
kinase family-interacting protein of 200 kDa; also
known as RB1CC1), ATG13, and ATG101 [19].
Once activated, the ULK1 complex further phos-
phorylates a number of downstream targets, which
culminate to promote autophagosome biogenesis
from the phagophore assembly site (PAS) at the
omegasome on the ER [20]. An important phosphor-
ylation target of the ULK1 complex to trigger
phagophore nucleation is the class III phosphatidy-
linositol-3-kinase complex 1 (PI3KC3eC1) [21],
consisting of VPS34 (vacuolar protein sorting 34;
the catalytic subunit), Beclin 1, ATG14L and VPS15
[22]. ULK1-mediated phosphorylation of the
PI3KC3eC1 components, such as Beclin 1, acti-
vates the VPS34 lipid kinase that causes the
production of the phospholipid, phosphatidylinositol
3-phosphate (PI3P), at the PAS [23]. PI3P then
recruits the PI3P-binding proteins, such as WIPI2
(WD repeat domain phosphoinositide-interacting
protein 2) and DFCP1 (double FYVE domain-
containing protein 1) to support the expansion of
the phagophore membrane [24,25]. Phosphorylation
of ATG9 by ULK1 also mediates the translocation of
ATG9-positive vesicles to the PAS, where they
supply lipid membrane to the expanding phagophore
[26].
The elongation of the phagophore is regulated by
two ubiquitin-like conjugation systems, which gen-
erate modified complexes of autophagy regulators
[27,28] (Fig. 1). The first ubiquitin-like reaction
involves the conjugation of ATG12 to ATG5 that is
catalyzed by the E1-like enzyme ATG7 and the E2-
like enzyme ATG10. The ATG5-ATG12 complex
then noncovalently interacts with ATG16L1 to formthe ATG5-ATG12-ATG16L1 ternary complex. The
second of the ubiquitin-like reactions involves the
conjugation of ubiquitin-like molecules of the ATG8
family with membrane-resident phosphatidylethano-
lamine (PE) [16,29]. The human ATG8 family
comprises of two subfamilies, microtubule-asso-
ciated protein 1 light chain 3 (MAP1LC3 or LC3)
and g-aminobutyric acid receptor-associated pro-
teins (GABARAPs), which are encoded by seven
genes expressing LC3A, LC3B, LC3B2, LC3C,
GABARAP, GABARAPL1 and GABARAPL2 (also
called GATE-16) [30]. Prior to lipidation, the ATG8
protein is processed at its C-terminal by a family of
cysteine protease, ATG4 [31]. Further, ATG7 and
ATG3 acting as the respective E1 and E2 enzymes,
and ATG12-ATG5-ATG16L1 complex serving as an
E3 ligase, conjugate ATG8 to PE, resulting in the
incorporation of ATG8-PE in the growing phago-
phore that aids in phagophore expansion, autopha-
gosome formation, and cargo recognition [16,29].
One of the autophagosome markers generally used
for studying autophagy is LC3B (referred herein as
LC3), which via this conjugation reaction, gets
converted from the cytosolic LC3-I form into the
membrane-bound LC3-II form [32].
After biogenesis, the maturation of autophago-
some occurs through fusion with the late endosome
and lysosome that is primarily coordinated by three
sets of proteins: Rab GTPases like Rab7, mem-
brane tethering complexes, such as HOPS (homo-
typic fusion and protein sorting) complex, and
SNARE (soluble N-ethylmaleimide-sensitive fac-
tor-attachment protein receptor) proteins like syn-
taxin-17 (STX17) and VAMP8 [13,14] (Fig. 1).
Several effector proteins of active GTP-bound
Rab7 drive autophagosome mobility and its fusion
with the late endosomal and lysosomal compart-
ments [33,34]. These include RILP (Rab-interacting
lysosomal protein) [35] and FYCO-1 (FYVE and
coiled-coil domain-containing protein 1) [36], which
respectively recruit dynein and kinesin motor
proteins for the perinuclear transport of mature
autophagosome. Other Rab7 effectors enabling
vesicle fusion include PLEKHM1 (Pleckstrin homol-
ogy domain-containing family member 1), which
acts as an adaptor by binding to both the HOPS
complex and LC3/GABARAP [37], and EPG5
(ectopic P-granules autophagy protein 5 homolog)
that binds to LC3 and stabilizes the autophagoso-
mal SNARE complex [38]. Interestingly, class III
phosphat idy l inos i to l -3 -k inase complex 2
(PI3KC3eC2), comprising of VPS34, Beclin 1,
VPS15, and UVRAG (UV radiation resistance-
associated gene protein), positively regulates
autophagosome maturation via the association of
UVRAG with the HOPS complex to activate Rab7
[39,40]. Besides HOPS, other tethering factors
driving autophagosome fusion events are ATG14L
[41] and TECPR1 (Tectonin beta-propeller repeat-
2757containing protein 1) [42]. The SNAREs involved in
autophagosome maturation form a complex
between the autophagosomal Q-SNAREs STX17
and SNAP29, and the late endosomal/lysosomal R-
SNARE VAMP8 [43], which is mediated by ATG14L
[41]. Additional regulators of autophagosome
maturation are GABARAPs [44], myosin VI [45],
BRUCE (Baculovirus IAP repeat-containing ubiqui-
tin-conjugating enzyme) [44], and phosphoinosi-
tides like PI4P (phosphatidylinositol-4-phosphate)
[46].
In the final steps, the inner membrane of the
autophagosome and the engulfed cytoplasm-
derived materials are degraded inside the autolyso-
some by the lysosomal acid hydrolases, which
include proteases, such as cathepsins (Fig. 1). The
breakdown products are then recycled and serve as
inputs for bioenergetics and anabolic pathways [47].
Autophagy receptors for mediating selective
autophagy
The autophagic response to starvation is the bulk
degradation of cytosolic materials that occurs in a
nonselective manner. However, other types of
cellular stresses, such as damaged organelles,
aggregated proteins, or pathogens, require their
selective sequestration into the autophagosomes for
degradation. Based on the remarkable substrate
specificity, selective autophagy is classified into
aggrephagy (clearance of protein aggregates),
mitophagy (clearance of mitochondria), pexophagy
(clearance of peroxisomes), ribophagy (clearance of
ribosomes), nucleophagy (clearance of nuclear
envelope), reticulophagy (clearance of ER), lyso-
phagy (clearance of lysosomes), xenophagy (clear-
ance of pathogens), lipophagy (clearance of lipid
droplets), and glycophagy (clearance of glycogen)
[48,49].
Selectivity in autophagy is conferred by the cargo
receptor proteins, which tether the ubiquitinated
cargo to the phagophore (Fig. 1). All cargo receptors
share common domains: the ubiquitin-binding
domain (UBD) through which they bind the specific
cargo [50], and the LC3-interaction region (LIR) motif
via which the interaction with the expanding phago-
phore occurs [51]. In mammalian cells, several cargo
receptor proteins are recognized, which include p62
(sequestosome-1 or SQSTM1) [52], OPTN (opti-
neurin) [53], NDP52 (nuclear dot protein of 52 kDa)
[54], TAX1BP1 (tax1 binding protein 1) [55], NBR1
(neighbor of BRCA1 gene 1) [56] and TOLLIP (Toll-
interacting protein) [57]. These receptors could be
recruited to different cargos in varying proportions
and/or may also cooperate in substrate selection.
For instance, p62/SQSTM1, NBR1, optineurin, and
TOLLIP play a role in executing aggrephagy [48].Several studies have revealed an intrinsic connec-
tion between autophagy receptors and neurodegen-
erative diseases. Some of these findings reported
that mutations in SQSTM1 could modify the genetic
susceptibility of Alzheimer’s disease [58], frontotem-
poral dementia [59], and amyotrophic lateral sclero-
sis [60].
Apart from ubiquitin-dependent selective autop-
hagy, there is an arsenal of receptor proteins, which
perform the process independent of ubiquitination
[61]. The most remarkable example is NIX, also
known as BNIP3L1 (Bcl-2-interacting protein 3 like),
which is a selective autophagy cargo receptor for
mitophagy in reticulocytes during the final stage of
erythroid maturation [62]. Others include FUNDC1
(FUN14 domain containing 1) [63], SMURF1
(SMAD-specific E3 ubiquitin-protein ligase 1) [64],
TRIM5a (tripartite motif-containing protein 5a) [65]
and STBD1 (starch-binding domain-containing pro-
tein 1) [66]. Besides the cargo receptors, there are
several key players like ALFY (autophagy-linked
FYVE protein, also known as WDFY3), which does
not harbor the UBD domain but acts as a scaffold by
getting associated with the ubiquitinated protein
aggregates and autophagosomal markers to facil-
itate aggrephagy [67].
Signaling pathways regulating autophagy
Diverse signaling pathways regulate autophagy,
but the most characterized one is nutrient signaling.
Nutrient deprivation (starvation) induces autophagy
by inhibiting the mechanistic target of rapamycin
(mTOR), which is a serine/threonine-protein kinase
that otherwise suppresses autophagy under nutrient
sufficiency [68] (Fig. 2). mTOR forms two distinct
protein complexes, which are mTOR complex 1
(mTORC1) and mTOR complex 2 (mTORC2) [69],
but only mTORC1 directly regulates autophagy by
phosphorylating the ULK1 complex and suppressing
the ULK1 kinase activity that is required to initiate
autophagy [19]. Besides ULK1 phosphorylation,
mTORC1 can also indirectly inhibit autophagy by
phosphorylating AMBRA1 (activating molecule in
Beclin 1-regulated autophagy protein 1), which, in
turn, could reduce ULK1 stability and its kinase
activity [70].
Additionally, mTORC1 can prevent autophagy by
phosphorylation-dependent cytoplasmic sequestra-
tion of TFEB (transcription factor EB), a master
transcriptional regulator of genes involved in lysoso-
mal biogenesis and autophagy [71] (Fig. 2). Particu-
larly for the autophagy process, TFEB regulates the
expression of genes required for autophagy initiation
(BECN1, ATG9B, WIPI1), phagophore elongation
(GABARAP, MAP1LC3B, ATG5), autophagosome
maturation (UVRAG, RAB7) and cargo recognition
Fig. 2. Regulation of autophagy by mTOR-dependent and mTOR-independent signaling pathways. Autophagy is
classically regulated by the mechanistic target of rapamycin (mTOR) pathway, in which the downstream mediators are the
ULK1 and PI3KC3eC1 complexes. AMPK can also directly influence ULK1 to govern autophagy. In addition, autophagy is
regulated by mTOR-independent pathways involving IP3, cAMP, Ca
2þ, and calpain. Various pharmacological inducers of
autophagy acting on specific targets in these pathways are shown.
2758(SQSTM1) [72]. Likewise, another serine/threonine-
protein kinase, Akt, can phosphorylate TFEB inde-
pendently of mTORC1 and prevent its nuclear
translocation [73]. Inhibition of mTORC1 or Akt
activity promotes autophagy via nuclear localization
of TFEB to enable the transcription of the target
genes [73,74]. Nuclear translocation of TFEB can
also occur via its dephosphorylation by the phos-
phatase calcineurin, which is activated during the
release of lysosomal Ca2þ through the Ca2þ
channel mucolipin 1 (MCOLN1) [75].
Another key regulator of autophagy is AMPK
(AMP-activated protein kinase), which is activated
during energy-deprived conditions [76]. Activated
AMPK can indirectly stimulate autophagy by sup-
pressing mTORC1 activity via phosphorylation of
RAPTOR (regulatory-associated protein of mTOR)and TSC2 (tuberous sclerosis complex 2) [77,78].
However, AMPK can directly induce autophagy
independently of mTORC1 via binding to and
phosphorylating ULK1 [79,80] (Fig. 2). Furthermore,
AMPK can phosphorylate Beclin 1 in PI3KC3eC1
that can be augmented by ATG14 to induce
autophagy [22].
Apart from the regulation of autophagy by
mTORC1 and AMPK, a number of mTORC1-
independent autophagy pathways have also been
described [81] (Fig. 2). Most of these pathways
involve second messenger molecules that nega-
tively influence autophagy when their intracellular
levels rise. These include IP3 (inositol 1,4,5-trispho-
sphate) [82], Ca2þ (calcium) [83,84], cAMP (30,50-
cyclic adenosine monophosphate) [83], and NO
(nitric oxide) [85]. While high levels of IP3, cAMP,
2759and NO suppress autophagosome biogenesis, Ca2þ
has complex effects on autophagy that are not fully
understood. For example, increased cytosolic Ca2þ
via influx from extracellular space through L-type
Ca2þ channels inhibits autophagosome formation
by activating the calpains (Ca2þ-dependent cysteine
proteases), whereas efflux of stored ER Ca2þ via IP3
receptors (IP3R) blocks autophagosome maturation
[83,84]. Some of these pathways are interconnected
and form a cyclic loop, wherein high cAMP levels
could increase IP3 production via the cAMP sensor
EPAC (exchange protein directly activated by
cAMP), the small G-protein RAP2B and PLCe
(phospholipase Ce), and subsequently IP3 influ-
ences ER Ca2þ release through the IP3R to elevate
cytosolic Ca2þ (which also increases via L-type
Ca2þ channels) that activates the calpains; which, in
turn, could increase cAMP levels by cleaving and
activating Gsa proteins [83]. Both mTORC1 and
mTORC1-independent pathways can be targeted by
small molecules for modulating autophagy.
Chemical modulators of autophagy
Chemical modulation of autophagy can be
achieved via directly inhibiting mTORC1 or by
targeting the mTORC1-independent pathways
[81,86] (Fig. 2). Some of the mTOR inhibitors
inducing autophagy include rapamycin [87] and its
analogs (rapalogs) temsirolimus (CCI-779) [88] and
everolimus (RAD-001) [89], and Torin 1 [90]. There
are a number of mTOR-independent autophagy
inducers acting via distinct mechanisms, which
include lithium, carbamazepine, and valproic acid
[82] (lowering intracellular inositol and IP3 levels),
trehalose [91,92] and metformin [93] (AMPK activa-
tion), verapamil [83], and felodipine [94] (reduction in
cytosolic Ca2þ levels), rilmenidine [83], (decrease in
cAMP levels), L-NAME [85] (inhibition of NO produc-
tion), and SMER28 [95] (mechanism not clear),
amongst many others. Additional means of inducing
autophagy include the natural compounds or nutri-
tional supplements, such as resveratrol [96,97]
(activation of sirtuin 1 and inhibition of mTOR),
spermidine [98] (increase in ATG gene expression),
and vitamin D3 [99,100] (increase in Beclin 1 and
ATG gene expression), or via the autophagy-indu-
cing peptide Tat-Beclin 1 [101], or via BH3 mimetics
like ABT737 [102] (disruption of Beclin 1eBcl-2
interaction).
The pharmacological modulation of autophagy
has attracted significant biomedical interests for the
treatment of myriad human diseases, including
neurodegenerative disorders [103]. For clinical
applications, mTOR-independent autophagy indu-
cers are considered to be safer with lesser side-
effects as compared to the mTOR inhibitors [81,86].
This is because mTOR governs critical cellular
processes like cell growth and protein synthesis[69], and thus, inhibiting mTOR for inducing autop-
hagy may not be ideal for long-term drug
administration.
Role of autophagy in neurodegenerative dis-
orders
Autophagy is implicated in diverse human dis-
eases, including neurodegenerative, infectious,
inflammatory, and metabolic diseases, as well as
myopathies and cancer [5,6]. Many of these pathol-
ogies occurring due to abnormal accumulation of
undesirable macromolecules are broadly classified
under macromolecule storage disorders, which
encompass several neurodegenerative and lysoso-
mal storage disorders [7,104,105]. Autophagy is
required for maintaining cellular homeostasis in
post-mitotic neurons, and improper functioning of
this process contributes to neurodegeneration. This
is evident from genetic studies in mice, where brain-
specific deletion of essential autophagy genes, such
as Atg5 or Atg7 to abrogate autophagy, resulted in
neurodegenerative phenotype [106,107]. Indeed,
autophagy dysfunction has been reported in almost
all the neurodegenerative disorders investigated,
and in certain conditions, induction of autophagy
ameliorated the disease phenotypes in transgenic
animal models [7,81,86,103,108]. These observa-
tions have led to the potential therapeutic possibi-
lities for autophagy modulation in these contexts.
However, emerging studies suggest that the
efficacy of autophagy modulators, as well as the
nature of the autophagy defects, may be context-
dependent. For example, a drug identified in
immortalized human or mouse cell lines showing
therapeutic benefits in transgenic animal models
may not be effective in the target organs of the
patients. With the advancements in human stem cell
technology, it is now possible to establish disease-
affected cellular platforms from patients for investi-
gating disease mechanisms and drug discovery in
the appropriate cell types, such as in neurons that
are otherwise not accessible.Human Induced Pluripotent Stem Cells:
Potential and Progress in Human
Disease Modeling and Drug Discovery
The intricate manner in which genetic components
are entangled with environmental exposures, a
factor, which constitutes the basis for virtually all
human disease, poses a significant challenge to
gaining a deeper understanding of pathologies,
which is often a prerequisite for the development of
novel therapies. To compound this, a large con-
tributor to disease burden in the modern world are
diseases, which are not monogenic [109]. Rather,
2760many pathologies arise when specific alleles of
multiple genes with interconnected functions,
although not always apparent, produce a genetic
predisposition to develop a disease given a degree
of certain environmental exposure within an anato-
mical system. Often the environmental element is
also a temporal one, namely aging, which precedes
the development of a disease. The mechanisms of
pathology may come to light when the genetic
background meets the environmental and temporal
influences in the context of an elaborate biological
structure. Therefore, it is these arenas with which
any relevant disease model must grapple in the
hopes of unveiling molecular workings of disease
and ultimately discovering therapies. Since theirFig. 3. Cellular reprogramming for hiPSC generation and po
drug discovery. A disease-affected patient serves as a source o
reprogrammed into human induced pluripotent stem cells (hiP
can be used to generate isogenic controls. hiPSCs are the
neurons, for the modeling of neurodegenerative diseases. Thus
genetic load, which is identical to disease-bearing individuals
modeling conditions, engrafted into animals, and subjected to
new therapeutic agents may be discovered, and a personalized
Derived cells may also be used for autologous transplantationderivation [110], human-induced pluripotent stem
cells (hiPSCs) have demonstrated considerable
promise in constituting a platform for effective
disease modeling (Fig. 3), while work continues to
be done in addressing these central aspects.
Nuclear reprogramming to pluripotency for gen-
erating patient-specific cell types
Cellular reprogramming and the direct conversion
approach have been fascinating areas of research
for the last two decades. The seeds of these
research fields were sown in 1962 when Sir John
Gurdon first reported that an adult nucleus could be
reprogrammed by an egg to produce an embryossible applications for hiPSC-based disease modeling and
f easily obtained somatic cells, which can subsequently be
SCs). Genetic editing technology, such as CRISPR/Cas9
n differentiated into disease-relevant cell types, such as
, disease modeling may be performed on a platform with a
. Such cells may be grown in two- or three-dimensional
high-throughput screening for drug discovery. Ultimately,
therapy plan may be used to benefit the individual patient.
after correction with genetic editing.
2761[111]. This nuclear reprogramming technique, which
was later termed somatic cell nuclear transfer
(SCNT), challenged the Waddington landscape
model in which the lineage of a committed cell was
permanent [112]. Following this discovery, a series
of studies in different models have demonstrated the
power of transcription factors in forcing alternative
cell fate. When ectopically expressed, some cell
type-specific transcription factors were shown to
induce a partial conversion process between two
different cell types. A master regulatory role was
attributed to these key master regulators in cell fate
determination [113e115]. In 2006, a game-changing
discovery was made by Takahashi and Yamanaka
when they demonstrated that pluripotency is achiev-
able through the overexpression of few master
transcription factors, namely, OCT4, SOX2, KLF4,
and MYC (OSKM) [110,116]. The resulting hiPSCs
were similar to human embryonic stem cells
(hESCs) in all examined parameters, including
morphology, proliferation, gene expression profile,
surface antigens, epigenetic marks of pluripotent
cell-specific genes, and telomerase activity
[117e120]. Furthermore, hiPSCs showed the same
capacity as hESCs to differentiate into cells of the
three embryonic germ layers via the teratoma assay
and by in vitro differentiation [110,121]. Derivation of
hESCs in vitro is not easily achieved due to limited
access to early human embryos. Therefore, this
astonishing ability to take fully adult cells and
reprogram them to pluripotency opens the opportu-
nity to utilize the reprogramming approach to
produce hiPSCs for modeling human diseases and
for drug discovery (Fig. 3).
Induction of pluripotency by different routes and
delivery systems
Since the OSKM combination produces hiPSCs
with low efficiency and with varying quality,
researchers have attempted to optimize the repro-
gramming process by modification of the reprogram-
ming factors, culture conditions, and cell type of
origin [121e127] (Fig. 3). Given the assumption that
it will be beneficial to reprogram cells without MYC,
which is a strong oncogene, scientists have repro-
grammed cells with OSK alone but with reduced
efficiency [128e130]. In addition, it has been shown
in human cells that both KLF4 and MYC can be
replaced by NANOG and LIN28 [121]. While in the
mouse system, many combinations were identified
which replace OSKM and even produce higher
quality cells [131e133], in the human system, it
has been more difficult to discover such combina-
tions. Interestingly, lineage specifiers were also
shown to induce pluripotency. GATA3, a mesendo-
dermal lineage specifier, was able to replace OCT4,
while ectodermal lineage specifiers like ZNF521,
SOX1, or SOX3 were able to replace SOX2 duringreprogramming [134,135]. While the current dogma
is that pluripotency is a result of a balanced cell state
between opposing lineage-specification pathways
[135], others proposed different explanations to the
capability of these factors to induce pluripotency
[136]. For example, the direct targets of the
functionally selected lineage specifiers are pluripo-
tency genes. Another explanation is that some of
these lineage specifiers are expressed at a devel-
opmental stage that is similar to that of the
preimplantation embryo, suggesting a potential role
in reprogramming for these factors [136].
Besides transcription factors, a major focus was
given to chromatin regulators, as cellular reprogram-
ming involves the erasure of the epigenome of the
cell of origin and the acquisition of an epigenetic
landscape resembling that of ESCs [137e140]. For
example, RCOR2, a member of a nucleosome
demethylation complex, was shown to replace
SOX2 in the classical Yamanaka factors [141].
Interestingly, inhibition of DOTL1 (H3K79 methyl-
transferase) by shRNA or pharmacological interven-
tions could replace KLF4 and MYC in the Yamanaka
factors during the induction of pluripotency [138].
These observations indicate that epigenetic modi-
fiers can take over the role of master regulatory
transcription factors in the establishment of
pluripotency.
A recent study aimed to understand the essential
genes that confer ESCs with growth and survival
capabilities [142]. To that end, haploid human
pluripotent stem cells (hPSCs) were subjected to a
genome-wide CRISPR/Cas9-mediated knockout
screen. Interestingly, many of the identified essential
genes encoded for transcription factors and proteins
related to cell cycle and DNA repair machinery,
which are important for normal growth. Among the
known pluripotency transcription factors, OCT4,
PRDM14, SALL4, and DPPA3 were identified as
part of the hPSC-essentialome [142]. These obser-
vations raise the question of whether the master
regulators and drivers of pluripotency can be
redefined in the context of somatic cell nuclear
reprogramming in order to yield hiPSCs with more
efficient and rapid reprogramming [142].
However, the reprogramming of fibroblasts into
hiPSCs with integrated viral vectors harbors a
limitation for regenerative medicine, since integra-
tions into the genome might increase the possibility
for genomic aberrations and cancer [121,129,143].
Therefore, considerable attempts have been made
to generate hiPSCs that bypass integrated vector-
based gene transfer. Successful reprogramming to
hiPSCs was done using adenoviruses, microRNAs,
episomal DNA, Sendai viruses, PiggyBac transpo-
sons, recombinant proteins, synthetic mRNAs, and
minicircles [143e152]. Reprogramming to hiPSC
was also shown to be possible with small molecules,
and yielded a more efficient reprogramming process,
2762albeit with the need for episomal vector induction
[153].
Primed versus naïve pluripotent stem cells
The hPSCs, which include both hESCs and
hiPSCs, harbor some limitations, which need to be
addressed. Conventional hESC derivation or hiPSC
production gives rise to developmentally advanced
or primed pluripotency cells in terms of their
transcriptional signatures and epigenetic marks,
defining their developmental stage to post-implanta-
tion [154e156]. Hence, producing hiPSCs resem-
bling preimplantation naive epiblast might hold a
higher potential for differentiation, as seen in the
mouse [157e160]. The first attempts to generate
authentic naïve hPSCs raised doubt as to their
usefulness in disease modeling and clinical applica-
tions because they were found to have a higher
degree of genomic instability when compared to
primed hPSCs [161,162]. Moreover, loss of genomic
imprinting existing in the current naïve hPSCs is
associated with human disorders and can also
potentially dysregulate the differentiation of hPSCs
into specific cell fates for disease modeling purposes
[163]. Therefore, optimization of culture conditions
will be required in order to address these features in
naïve hPSCs in order to use them as an intrinsic
model for disease modeling [164].
Altogether, the process of direct reprogramming of
fibroblasts into hiPSCs holds great promise for
modeling human diseases and for generating
patient-specific cell types for drug discovery. This
cellular model alleviates the ethical issues that are
linked with hESCs, and also solves the unavailability
issues of these cells; hence, facilitating the flourish-
ing of hiPSC-based therapies [165].
Achieving disease-relevant human cell cultures
The hPSCs (i.e., hESCs and hiPSCs) are capable
of both self-renewal and differentiation into any cell
of embryonic origin [166]. Therefore, hPSCs offer an
effectively indefinite source of differentiated disease-
relevant cells (Fig. 3). This is crucial in modeling
human pathologies, as many cell types are near
impossible to isolate and culture, both technically
and ethically, and have a limited proliferative
capacity. Furthermore, readily available human
cells avoid discrepancies due to evolutionary diver-
gence between humans and animal models. Still, the
utility of hPSCs in this context hinges on the
refinement of reliable differentiation protocols into
relevant cell identities. It might be for this reason that
neurological and neurodegenerative diseases are at
the forefront of disease modeling using hPSCs, as
protocols for neuronal differentiation from hPSCs are
relatively advanced [167]. Besides these, other
types of cells for which differentiation protocolshave been developed include cardiomyocytes
[168], pancreatic beta cells [169], hematopoietic
cells [170], renal cells [171,172], intestinal cells
[173,174], cells of the lung [175,176], and others. In
this manner, the establishment of workable in vitro
platforms for the study of specific disease-asso-
ciated and disease-affected human cell types is
attainable. Notwithstanding, while it is extremely
useful to have established cultures of specific
disease-affected cells, some phenotypes of a
disease are not manifested in a two-dimensional
culture system. Therefore, it is advantageous that
more complex structures be utilized, ones in which
the three-dimensional interactions between multiple
cell subtypes are taken into account. This is partly
being addressed by the development of three-
dimensional organoid cultures, which replicate in
vivo cell-cell interactions to some degree. Using
PSCs to create human-animal chimeras, although
provoking considerable ethical concerns [177], takes
this a step further and allows for the consideration of
interactions between different anatomical systems in
the development of the disease. A comprehensive
overview of current research in human disease
modeling using three-dimensional culture and
human-animal chimeras has been published
recently [178].
hiPSCs for modelling genetically simple and
complex human diseases
While hESCs are derived from an early embryo,
hiPSCs are the product of cellular reprogramming of
somatic cells, as discussed above. hESCs have
been used to model genetic disease by way of gene
expression knockdown [179], inducing a disease-
relevant gene mutation [180], by employing hESCs
derived from diseased embryos that have under-
gone preimplantation genetic diagnosis (PGD) [181]
and by utilizing aneuploid hESCs that emerge
spontaneously in culture [182]. Conversely, dis-
eases that are genetically complex, have unknown
genetic components and have no available preim-
plantation screening tests, cannot be modeled in the
aforementioned methods. In such cases, patient-
derived hiPSCs have the unique ability to serve as a
platform, which is faithful to the genetic background
of the patient, ensuring complete conservation of the
genetic components of any particular disease in the
disease model and without the need for genetic
editing. Thus, the ability to produce patient-specific
hPSCs is the crux of employing hiPSCs as powerful
tools in disease modeling (Fig. 3). They also allow for
the derivation of disease-relevant cells from patients
of all ages. In this way, cell-level phenotypes,
specifically in the patient-derived cells, have been
uncovered in relatively genetically simple childhood
diseases like spinal muscular atrophy (SMA) [183],
and genetically complex adult-onset diseases, such
2763as schizophrenia [184,185]. Examples of diseases
that have been studied using two- and three-
dimensional hiPSC-derived culture systems include
gastrointestinal diseases, such as Hirschsprung
disease [186], autism spectrum disorder (ASD)
[187,188], Parkinson’s disease (PD) [189] and
Alzheimer’s disease (AD) [190], among many
others.
hiPSCs in drug discovery and drug screening
Understanding the molecular mechanisms under-
lying pathology is an important step in the develop-
ment of targeted therapies. Moreover, hiPSC-
derived disease models can serve as a more direct
platform for drug discovery, as candidate drugs can
be directly tested using patient-derived cells. Differ-
entiated disease-relevant cells from large cohorts or
from individual patients can be subjected to treat-
ment with specific candidate drugs, or simulta-
neously with a large number of compounds using
high-throughput screening (HTS) (Fig. 3). In both
cases, an observable phenotype, or set of pheno-
types, must be defined in order to evaluate the
efficacy and potency of tested compounds in the
setting of the specific disease model. Numerous
therapeutic agents have been tested in this way for
multiple diseases, including amyotrophic lateral
sclerosis (ALS) [191], AD [192], SMA [193], and
achondroplasia [194]. In the case of HTS, this
phenotype must be capable of being measured via
automated analysis. This may not be suitable when
the disease phenotype is difficult to quantify, or if a
system which would allow automatic quantification
would be extremely laborious to develop. In other
cases, such as with quantification of cell proliferation
or measurement of fluorescent signal of a reporter
gene, which can be targeted in the iPSC state, HTS
has the advantage of allowing testing of over one
million compounds simultaneously [195], without the
need for prior knowledge about the drug mechanism.
This allows the possibility of testing a large number
of drugs, which have already been approved for use
in humans for possible repositioning thereof in other
diseases, thereby expediting clinical trials and new
treatment options. Such systems have been
employed in the study of AD [196], familial dysau-
tonomia [197], and ALS [195]. Achieving rapid drug-
screening for patient-derived model systems could
facilitate a breakthrough in personalized medicine,
as the response to various drugs could be tested on
individual patient cells. They also allow screening for
drug toxicities on specific and possibly individual
human tissues, most commonly hepatotoxicity [198],
cardiotoxicity [199], and neurotoxicity [200]. Thor-
ough reviews of current disease models and drug
screening have been published previously
[127,201].hESCs versus hiPSCs: shared and distinct
challenges
While the topic has been under some debate
[202], it is generally believed that hiPSCs hold similar
potentials to hESCs in their capacity to differentiate
into various cell types. Still, in a few instances,
diseases in which both hESC-based and hiPSC-
based models have been developed, diverging
phenotypes have been observed. Such is the case
with fragile X syndrome (FXS), which was first
modeled in hESCs derived from early embryos
diagnosed using PGD [181] and later compared
with a patient-derived hiPSC model [203]. In the
hESC model, the FMR1 gene, which is aberrantly
silenced in FXS, was active in undifferentiated cells
and silenced upon differentiation. In contrast, in
patient-derived undifferentiated hiPSC lines, the
FMR1 gene was silenced. This highlights a potential
difference between hESC and hiPSC disease
models, especially in the context of diseases
involving aberrant epigenetic processes. One rea-
son for this could be variations in the reprogramming
process, whereby some colonies may maintain
aberrant epigenetic patterns, which do not fully
mirror hESCs due to incomplete reprogramming,
thus causing inconsistencies in expression between
hiPSC colonies and hESCs [204]. Nevertheless,
both models are potentially useful following differ-
entiation into disease-relevant cells.
A further challenge, namely variations between
hiPSCs derived from different individuals, must also
be taken into account [205,206]. Therefore, strict
controls must be employed to avoid confounding
factors due to background genetic variability. When
disease-relevant mutations are known, these should
include isogenic controls generated using gene-
editing techniques to correct the disease-inducing
mutation [207]. In other cases, large cohorts of
patient-derived iPSCs must be employed in order to
identify authentic disease phenotypes. This endea-
vor is aided by the establishment of hiPSC reposi-
tories derived from a vast array of disease-affected
individuals [208].
The development and progression of many dis-
eases, such as AD and PD, are highly affected by
aging [209]. These diseases are pertinent to study,
especially in the context of an aging world population
[210]. One drawback of using differentiated hPSCs
as a basis for disease models is that the reprogram-
ming of adult cells into hiPSC abolishes cellular
aging. Thus, subsequently, differentiated cells tend
to retain fetal characteristics, thus impeding the
ability to model diseases in which aging is a central
component. This phenomenon has been reported in
differentiation into hematopoietic cells [211], neu-
rons [212], pancreatic beta cells [213], intestinal
organoids [214], and others. Because of this, various
2764strategies have been employed in an attempt to
induce cellular aging in hPSC-differentiated cells
[215]. One attempt to overcome this barrier is by
forced expression of progerin, the truncated lamin A
protein that accelerates aging in Hutchinson-Gilford
progeria syndrome, in differentiated cells [216]. By
overexpression of progerin, late-onset characteris-
tics of PD were induced in neurons, which were
differentiated from patient-derived hiPSCs [216].
Similarly, hiPSC-differentiated neurons in which
telomere-shortening was employed also resulted in
phenotypes characteristic of aging cells [217].
Interestingly, neurons derived from fibroblasts by
the direct reprogramming method, rather than byFig. 4. Generation of human neurons from hPSCs. Classic
stem cells (hPSCs) into the neural lineage involve neural induc
cultures into neural precursors (NPs). This can be followed by f
neurons by exposing the cells to appropriate morphogens and
and more rapid differentiation of hPSCs into neurons can be a
relevant transcription factors. Cerebral organoids are derived
These organoids represent a miniature of the developing huma
tissue architectures. All these methods serve widely as platform
human brain, serving as a powerful system to study neurodevachieving a pluripotent stage, did retain aging-
associated gene signatures, unlike their hiPSC-
derived counterparts [218,219].Neural Differentiation of Human
Pluripotent Stem Cells
Since the first derivation of hESCs [166,220], and
later the advent of cellular reprogramming to hiPSCs
[110], numerous studies have utilized these pluripo-
tent stem cells (will refer collectively as hPSCs) for
neural differentiation. The ability to generate human
neurons from hPSCs allow researchers to study theal approaches for the differentiation of human pluripotent
tion in 2D (adherent) or 3D (through embryoid bodies; EBs)
urther differentiation and neural patterning into subtypes of
/or relevant small molecules in adherent cultures. Directed
chieved by overexpression of a single or a combination of
from 3D cultures of hPSCs-derived EBs or NP-clusters.
n brain and may contain a similar neuronal complexity and
s to differentiate hPSCs into the different cell types of the
elopmental and neurodegenerative disease in vitro.
2765aspects of human neural differentiation, its patholo-
gies in diseases, and to serve as a valuable source
for cell therapy applications and drug development
[221,222] (Fig. 4). These hPSC-derived neural cells
also enable the studies on autophagy in physiologi-
cal or disease-affected human cellular platforms that
are relevant to human biology [223,224].
Neural induction
The first step in neural differentiation of hPSCs is
essentially switching from the self-renewal state to
neural induction (Fig. 4). Historically, neural cultures of
primary neural progenitors and stem cells involved the
formation of neural spheroids [225]. Presumably, for
that reason, the initial protocols for neural induction
and differentiation of hPSCs to neural precursors
(NPs) involved the formation of hPSCs aggregates. In
these protocols, the switching from self-renewal state
to neural induction was triggered by spontaneous,
uncontrolled differentiation of prolonged culture of
hPSCs as colonies or in three-dimensional, free-
floating hPSCs-aggregates, termed embryoid bodies
(EBs) or neurospheres, followed by lineage selection
toNPs [226e228]. To further induce neural differentia-
tion, some of the early methods used retinoic acid
(RA), coculturing of hPSCs with mouse stromal cells,
or mechanically dissecting “neural differentiating
zones” of hPSCs colonies [226,227,229]. However,
generating progenitor cells using these aggregation
approaches displayed cells with a wide range of
developmental stages.To this end,methods for further
isolating neural tube-like structures, termed “neural
rosettes,” or sorting cells based on early neural
markers (like PSA-NCAM) were applied to purify the
NPs in cultures [226,228,230].
For better neural induction methods, researchers
searched for growth factors, which will enable a more
controlled and efficient neural induction of hPSCs. At
first, the inhibition of bone morphogenetic protein
(BMP) signalingwas identified to significantly enhance
the enrichment levels for NPs within the differentiating
hPSCs by suppressing the differentiation of hPSCs
into lineages other than the neural one [231e233].
Hence, initially, noggin-mediated blockage of endo-
genous BMP signaling and later by small molecules,
such as LDN-193189 or dorsomorphin, were shown to
support neural induction and differentiation of hPSCs
to NPs. Next, a second pathway involving TGFb was
identified that could be targeted for more efficient
conversion of hPSCs to NPs. The small molecule
TGFb inhibitor, SB431542, was shown to inhibit the
Lefty/Activin/TGFb pathways by blocking the phos-
phorylation of ALK receptors 4, 5, and 7. While the
Activin/Nodal pathway has been implicated in the
pluripotency of hPSCs [234], its inhibition by
SB431542 enhanced the ability of hPSCs to exit their
self-renewal; thereafter leading to improved neural
induction efficiency of hPSCs [235].Chambers and colleagues introduced the syner-
gistic action of inhibition of both BMP and TGFb
pathways, leading to inhibition of their respective
downstream SMAD effectors (SMAD1/5/8 for BMP,
and SMAD2/3 for TGFb signaling); hence, termed
“dual-SMAD inhibition” by using the combination of
Noggin (and later, LDN-193189) and SB431542 to
greatly facilitate the differentiation of hPSCs to NPs
and in a shorter time period [236,237]. Moreover,
with the identification that EB-based protocols might
present uneven distribution of growth factors and/or
small molecules to the differentiating cells that could
result in heterogeneous differentiation, Chambers
and colleagues presented one of the first reports for
differentiating hPSCs in monolayer cultures with
highly efficient neural conversion; thus bypassing
the hurdles associated with EBs [236]. Nowadays,
most laboratories use mixed methods, which are
mostly based on the EBs/neurospheres and the
“dual-SMAD inhibition” protocols. Finally, the NPs
could be further differentiated into different neural
lineages, such as astrocytes, oligodendrocytes, and
neurons, and to cells of the human retina.
Neuronal subtype specification
The NPs differentiated from hPSCs via the EB/
neurospheres or dual-SMAD inhibition methods
carry an anterior identity. When normally expanded
and cultured in the presence of basic fibroblast
growth factor (bFGF) and epidermal growth factor
(EGF), these NPs will eventually be committed to
forebrain fates. However, in the presence of different
morphogens and/or small molecules, the NPs can
acquire definitive regional identities [238]. Generally,
WNT, FGF, and RA are used for caudalization
(posterior identity). Activation of the WNT pathway
showed a dose-dependent effect in patterning NPs
to the forebrain (low concentrations), midbrain,
hindbrain, and spinal cord (high concentrations)
identities [239], while the gradients of RA and
FGFs governed the spinal cord segmentation
identities [240,241]. NPs can be specified not only
along the anterior-posterior axis but also to the
dorsoventral axis. Sonic hedgehog (SHH) is a
ventralization morphogen, whereas BMPs and
WNT are more dorsal morphogens [242,243].
Following these principles, the combinations of
different morphogens permit to pattern the NPs into
specific neural subtypes that are to be derived from
these NPs, such as cortical neurons (forebrain;
dorsal), dopaminergic neurons (midbrain; ventral) or
motor neurons (spinal cord; ventral). The ability to
differentiate hPSC-derived NPs into specific neural
subtypes is of great potential for studying human
neurodegenerative disorders in the most relevant,
disease-affected human cell types, such as midbrain
dopaminergic neurons for PD or motor neurons for
ALS [244,245] (Fig. 4).
2766Directed differentiation by transcription factors
In the last decade, multiple studies have shown
efficient cell fate reprogramming only by forced
expression of single or multiple transcription factors
(Fig. 4). In an effort to produce neurons, forced
expression of three transcription factors (Brn2,
Ascl1, and Myt1) were proven to reprogram mouse
fibroblasts into functional neurons, termed induced
neurons (iN) [246]. This was immediately followed by
several studies, which used a similar approach to
directly differentiate hPSCs into neurons by forced
overexpression of relevant transcription factors, thus
bypassing the need to first differentiate to NPs and
also significantly shortening the differentiation pro-
cesses for generating neurons in vitro. These
multiple studies showed that a single factor, such
as ASCL1, NEUROD1, or NEUROG2, can efficiently
drive hPSCs into pure excitatory neurons in less
than two weeks [247,248]. This single factor-directed
differentiation to human neurons gave rise to
neurons with cellular, electrophysiological, and
molecular characteristics of excitatory neurons. For
inducing specific subtypes of neurons, the forced
expression of a combination of transcription factors
was utilized to drive reprogramming into specific
neurons. For example, the coexpression of ASC-
L1and DLX2 was found to be sufficient to directly
differentiate hPSCs into GABAergic interneurons,
which are the inhibitory neurons that balance
neuronal excitation in the brain [249]. Similarly,
ASCL1, NURR1, and LMX1A were found to drive
hPSCs directly into dopaminergic neurons, while
coexpression of NEUROG1, NEUROG2, NEU-
ROG3, NEUROD1, and NEUROD2 induced direct
differentiation of hPSCs into motor neuron [250,251].Cerebral Organoids
Specific neural subtypes derived from hPSCs may
be valuable for disease modelling, drug discovery,
and toxicity assays. However, these differentiated
neurons still lack the complexity characteristic of the
brain tissue. In order to apply a more holistic
approach for studying human development using
hPSCs, researchers invested their effort to develop
an in vitro model of a complex tissue derived from
hPSCs. A pioneering study first demonstrated the
ability of self-organization of hPSCs aggregates to
form complex, multicell type optic cup structures
[252]. In a similar manner, another method was
established to form a three-dimensional organoid
culture-system from hPSC-derived EBs, termed
cerebral organoids, which developed various dis-
crete brain regions with self-organization and mini-
mal exogenic cues [253]. Subsequent studies of
multiple research-groups have shown that human
organoid cultures enabled cells to differentiate intomature and functional neurons in structures and
contexts resembling the developing human cortex
[254e257]. This fast-growing field presented a
“renaissance” to the EBs-based neural induction
method. Multiple methods are now used to culture
cerebral organoids from hPSCs and/or NPs aggre-
gates in culture conditions for growing region-
specific brain-like structures, i.e., the cerebellum,
hypothalamus, or the hippocampus [258e260]. The
cerebral organoid differentiation approach enables
the study of different aspects of human diseases,
such as microcephaly, dementia, autism, and Zika
viral infection [261e265]. Moreover, these organoids
can be cultured over a long period of time and
provide access to a large diversity of cell types,
including subtypes of neurons and cells of the
astroglial lineages [266,267] (Fig. 4).Human Pluripotent Stem Cell Models of
Neurodegenerative Diseases as a
Disease-Relevant Platform for Studying
Autophagy
Autophagy has attracted significant attention for
hiPSC-based studies of neurodegenerative disor-
ders. Since impairment of this vital homeostatic
process contributes to neurodegeneration, defective
autophagy is being utilized in recent years as a
phenotypic readout in hiPSC-derived neurons
[223,224] (Fig. 5). This provides an appropriate
disease-affected human cellular platform for inves-
tigating the mechanisms of autophagy dysfunction
and the drug discovery of autophagy modulators in a
manner relevant to human biology. Several hiPSC
models of neurodegenerative diseases (Table 1),
where impairment of autophagy has been studied
(Table 2) and autophagy modulators, have been
assessed for therapeutic benefits (Table 3), are
described below.
Alzheimer’s disease
Alzheimer’s disease (AD) is themost common type
of progressive dementia. AD is associated with
abnormal metabolism of amyloid precursor protein
(APP), which leads to the formation of extracellular
senile plaques made of amyloid-b (Ab) [268]. Autop-
hagy is implicated in the production of Ab depositions,
as they have been shown to be generated inside the
autophagosomes, where APP is processed by the
enzyme presenilin-1 (PS1) into Ab that is then either
degraded or secreted in the extracellular space to
form plaques [269e271]. This is supported by the
accumulation of autophagosomes, characteristic for
an autophagy block, observed in the post-mortem
brain samples from AD patients, and in the neurites of
PS1/APP mutant mice [272]. The AD-associated
Fig. 5. Impairment of autophagy in neurodegenerative diseases. Impairment of autophagy at distinct stages of the
process, such as at the level of autophagosome formation, cargo recognition, or autophagosome maturation, has been
described in multiple neurodegenerative diseases. The impact on autophagy due to mutations or loss of disease-
associated proteins in non-hiPSC and hiPSC models is indicated (by red arrows). In addition, the point mutants of a-
synuclein and LRRK2 associated with PD also impair chaperone-mediated autophagy (not shown).
2767gene most studied for autophagy is PSEN1, the gene
encoding for PS1, which has been suggested to be
required for lysosomal targeting of the proton pump,
v-ATPase V0a1 subunit, for maintaining the acidic pH,
whereas mutant PS1 has been shown to impair
lysosomal acidification and function that conse-
quently block autophagosome maturation and autop-
hagic flux in mammalian cell lines [273,274].
However, PS1/2 double knockout mouse embryonic
fibroblasts (MEFs) displayed reduced autophago-
some number due to impaired biogenesis, as well as
dysregulation of nutrient sensing by mTORC1 and
dysfunctional mTORC1/TFEB-driven CLEAR gene
network activity [275]. Despite the autophagy defect,
the pharmacological induction of autophagy was
beneficial by clearing Ab plaques and tau tangles,
and rescuing the disease pathogenesis in various AD
mouse models. These effects have been demon-strated in APP/Tau/PS1 mutant (3xTg-AD) mice with
rapamycin [276,277] and carbamazepine [278]; in
APP/PS1 mutant mice with rapamycin [279], treha-
lose [280], carbamazepine [281], and gypenoside
XVII (GP-17) [282]; in APP mutant mice with
rapamycin [283], trehalose [284], and latrepirdine
[285]; and in APOE4 mutant mice with rapamycin
[286].
With the emergence of patient-derived hiPSC
models, a number of hiPSC-based neuronal plat-
forms have been generated to study the pathogen-
esis of AD. Since PSEN1 is the most commonly
mutated gene in familial AD (FAD), multiple studies
have utilized AD patient-derived hiPSC models with
PSEN1 gene mutations. The autophagic block
observed in cellular and in vivo models of AD with
PSEN1 mutations is consistent with some, but not
all of the studies in AD hiPSC models carrying this
Table 1. List of patient-derived hiPSC lines of neurodegenerative disorders where autophagy has been studied.
Mutant
gene
Mutant
protein
Patient-derived hiPSC lines of
neurodegenerative disorders
Gene mutation Origin of patient-derived
hiPSC lines
Reference
Alzheimer’s disease (AD)
PSEN1 Presenilin-1 PSEN1 Y115C PSEN1(Y115C) Patient dermal fibroblasts [288]
PSEN1 M146I PSEN1(M146I) Patient dermal fibroblasts [288]
PSEN1 Intron4 PSEN1(Intron4) Patient dermal fibroblasts [288]
PS1-M146L PSEN1(M146L) Patient dermal fibroblasts [275]
PS1-A246E PSEN1(A246E) Patient dermal fibroblasts [275]
PS1 M146L (7889(S)B) PSEN1(M146L) Patient dermal fibroblasts [291]
FAD1 iPSC (7671C) PSEN1(A246E) Patient dermal fibroblasts [287]
PS1-4 iPSC Not specified Patient dermal fibroblasts [290]
PS1-E120K PSEN1(E120K/wt) Patient blood mononuclear
cells
[289]
APP APP APP V717I APP(V717I) Patient dermal fibroblasts [288]
APPdup APP(Duplication) Patient dermal fibroblasts [288]
Ts21 Trisomy chromosome
21
Patient dermal fibroblasts [288]
Tauopathies, including frontotemporal dementia (FTD)
MAPT Tau 19-L3-RC3 MAPT(A152T /þ) Patient dermal fibroblasts [308]
19-L5-RC6 MAPT(A152T /þ) Patient dermal fibroblasts [308]
Tau6-1-RC1 MAPT(A152T /þ) Patient dermal fibroblasts [308]
GRN Progranulin GRN-1 GRN(R493X) Patient dermal fibroblasts [310]
GRN-2 GRN(R493X) Patient dermal fibroblasts [310]
GRN-3 GRN(R198GfsX19) Patient dermal fibroblasts [310]
Parkinson’s disease (PD)
SNCA a-synuclein A53T SNCA #1 (SFC828-03) SNCA(A53T) Patient dermal fibroblasts [338]
A53T SNCA #2 (SFC829-03) SNCA(A53T) Patient dermal fibroblasts [338]
A53T SNCA #3 (SFC830-04) SNCA(A53T) Patient dermal fibroblasts [338]
SNCA Tripl #1,2,3 (SFC831-03) SNCA(Triplication) Patient dermal fibroblasts [338]
LRRK2 LRRK2 LRRK2-PD (SP05) #1,2) LRRK2(G2019S) Patient keratinocytes and
dermal fibroblasts
[342]
LRRK2-PD (SP06) #1,2) LRRK2(G2019S) Patient keratinocytes and
dermal fibroblasts
[342]
LRRK2-PD (SP12) #3,4) LRRK2(G2019S) Patient keratinocytes and
dermal fibroblasts
[342]
LRRK2-PD (SP13) #2,4) LRRK2(G2019S) Patient keratinocytes and
dermal fibroblasts
[342]
LA iPSC #5,11 LRRK2(I2020T) Patient dermal fibroblasts [345]
LB iPSC #16,21 LRRK2(I2020T) Patient dermal fibroblasts [345]
LRRK2-G2019S LRRK2(G2019S) Patient dermal fibroblasts [328]
LRRK2 G2019S-iPSC LRRK2(G2019S) Patient dermal fibroblasts [344]
Amyotrophic lateral sclerosis (ALS)
SOD1 SOD1 ALS1 (SOD1 L144FVX) (A3316) SOD1(L144FVX) Patient dermal fibroblasts [387]
ALS2 (SOD1 L144FVX) (A3536) SOD1(L144FVX) Patient dermal fibroblasts [387]
ALS3 (SOD1 G93S) (A37228) SOD1(G93S) Patient dermal fibroblasts [387]
SOD1 iPSC SOD1(N139K) Patient dermal fibroblasts [392]
TARDBP TDP-43 TDP-43 M337V iPSC TARDBP(M337V) Patient dermal fibroblasts [195]
C9orf72 C9orf72 C9-T2 #6,7 C9orf72(510690 R.E. #6,
420640 R.E. #7)
Patient dermal fibroblasts [390]
C9-7245 #1,3 C9orf72(1210 R.E. #1, 1380
R.E. #3)
Patient dermal fibroblasts [390]
C9-02 #2,10 C9orf72(1000 R.E. #1, #3) Patient dermal fibroblasts [390]
C9orf72 iPSC #1,2,3 C9orf72(~800 R.E.) Patient dermal fibroblasts [392]
iPS21c1 C9orf72(R.E.) Patient dermal fibroblasts [395]
iPS21cx C9orf72(R.E.) Patient dermal fibroblasts [395]
iPS31c8 C9orf72(R.E.) Patient dermal fibroblasts [395]
Carrier 1 #5,6 C9orf72(>1000 R.E.) Patient dermal fibroblasts [391]
Carrier 2 #1,11 C9orf72(>1000 R.E.) Patient dermal fibroblasts [391]
TBK1 TBK1 mTBK1-I TBK1(T77WfsX4) Patient keratinocytes [389]
mTBK1-II TBK1(E643del) Patient keratinocytes [389]
mTBK1-FUS TBK1(Y185X) Patient keratinocytes [389]
Huntington’s disease (HD)
HTT Huntingtin HD-iPShom 4F #1,2 HTT(42/44 CAG repeats) Patient dermal fibroblasts [409]
HD-iPShom 3F #1,2 HTT(42/44 CAG repeats) Patient dermal fibroblasts [409]
HD-iPShet 3F #1 HTT(17/45 CAG repeats) Patient dermal fibroblasts [409]
iPSHD22 HTT(47/16 CAG repeats) Patient dermal fibroblasts [410]
D-HD-iPSC HTT(109 CAG repeats) Patient dermal fibroblasts [411]
F-HD-iPSC HTT(50 CAG repeats) Patient dermal fibroblasts [411]
iPSC-HDQ47 HTT(47 CAG repeats) Patient dermal fibroblasts [412]
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Tab l e 1 (continued)
Mutant
gene
Mutant
protein
Patient-derived hiPSC lines of
neurodegenerative disorders
Gene mutation Origin of patient-derived
hiPSC lines
Reference
Multiple System Atrophy (MSA)
(Sporadic) (Sporadic) MSA-P1 (Sporadic) Patient dermal fibroblasts [423]
MSA-P2 Patient dermal fibroblasts [423]
MSA-C1 Patient dermal fibroblasts [423]
MSA-C2 Patient dermal fibroblasts [423]
Gaucher disease (GD)
GBA1 GCase GD-1 #1 (MNG-09-232) GBA1(N370S/N370S Patient dermal fibroblasts [441]
GD-2a #13,16 (MNG-09-246) GBA1(W184R/D409H) Patient dermal fibroblasts [441]
GD-2b #3,4 (MNG-10-257) GBA1(L444P/RecNciI) Patient dermal fibroblasts [441]
GD-3 #1,4 (MNG-98-12-9) GBA1(L444P/L444P) Patient dermal fibroblasts [441]
GBA-PD-1 #1,2 (MK071) GBA1(N370S/wt) Patient dermal fibroblasts [442]
GBA-PD-2 #1 (MK088) GBA1(N370S/wt) Patient dermal fibroblasts [442]
GBA-PD-3 #1,2 (SFC-834-03) GBA1(N370S/wt) Patient dermal fibroblasts [442]
GD GBA1(N370S/84GG) Patient dermal fibroblasts [436]
PD-1 GBA1(RecNcil/wt) Patient dermal fibroblasts [438]
PD-2 GBA1(L444P/wt) Patient dermal fibroblasts [438]
PD-3 GBA1(N370S/wt) Patient dermal fibroblasts [438]
PD-4 GBA1(N370S/wt) Patient dermal fibroblasts [438]
GD-1 GBA1(L444P/L444P) Patient dermal fibroblasts [438]
GD-2 GBA1(N370S/N370S) Patient dermal fibroblasts [438]
Niemann-Pick type C1 (NPC1) disease
NPC1 NPC1 NPC1-1 #4,13 (WIBR-IPS-NPC1I1061T/
I1061T)
NPC1(I1061T/I1061T) Patient dermal fibroblasts [454]
NPC1-2 #9,26 (WIBR-IPS-NPC1P237S/
I1061T)
NPC1(P237S/I1061T) Patient dermal fibroblasts [454]
NPC1-3 #4,47 (WIBR-IPS-NPC11920DG/
1009G>A)
NPC1(1920DG/1009G>A) Patient dermal fibroblasts [454]
N P C 1 - 4 # 1 7 , 2 0 ( W I B R - I P S -
NPC11920DG/1009G>A)
NPC1(1920DG/1009G>A) Patient dermal fibroblasts [454]
hNPC #3,17 NPC1(P237S/I1061T) Patient dermal fibroblasts [450]
NPC1 NPC1(P237S/I1061T) Patient dermal fibroblasts [455]
Spinocerebellar Ataxia (SCA)
ATXN3 Ataxin-3 SCA3-iPS #1,2 ATXN3(81 CAG repeats) Patient dermal fibroblasts [470]
PRKCG PKCg SCA14-H36R-1 #1,18 PRKCG(H36R exon 1) Patient dermal fibroblasts [471]
SCA14-H36R-2 #3,12 PRKCG(H36R exon 1) Patient dermal fibroblasts [471]
SCA14-H101Q-1 #1,10 PRKCG(H101Q exon 4) Patient dermal fibroblasts [471]
SCA14-H101Q-2 #3,14 PRKCG(H101Q exon 4) Patient dermal fibroblasts [471]
Spinal bulbar muscular atrophy (SBMA)
AR And r o g e n
receptor
SBMA-1-AR-CAG44 #C1,C3,C4 AR(44 CAG repeats) Patient dermal fibroblasts [474]
SBMA-2-AR-CAG50 #C1,C2,C5 AR(50 CAG repeats) Patient dermal fibroblasts [474]
SBMA-3-AR-CAG48 #C2,C3,C4 AR(48 CAG repeats) Patient dermal fibroblasts [474]
SB6 #MP2,MP3 AR(62 CAG repeats) Patient dermal fibroblasts [486]
SB18 AR(68 CAG repeats) Patient dermal fibroblasts [486]
Charcot-Marie-Tooth (CMT) disease
MFN2 Mitofusin 2 CMT2A-1 #1,2,3 MFN2(A383V) Patient dermal fibroblasts [493]
CMT2A-2 #1,2,3 MFN2(A383V) Patient dermal fibroblasts [493]
Abbreviations e AD: Alzheimer’s disease; ALS: Amyotrophic lateral sclerosis; APP: Amyloid-b precursor protein; AR: androgen receptor;
C9orf72: Chromosome 9 Open Reading Frame 72; CMT: Charcot-Marie-Tooth disease; FTD: Frontotemporal dementia; GCase:
Glucocerebrosidase; GD: Gaucher disease; HD: Huntington’s disease; HTT: Huntingtin; iPSC: induced pluripotent stem cells; LRRK2:
Leucine-rich repeat kinase 2; MSA: Multiple system atrophy; NPC1: Niemann-Pick type C 1; PD: Parkinson’s disease; PKCg: Protein
kinase Cg; PS1: presenilin-1; R.E.: Repeat expansion; SBMA: Spinal bulbar muscular atrophy; SCAs: Spinocerebellar ataxias; SOD1:
superoxide dismutase 1; TBK1: TANK-binding kinase 1; TDP-43: TAR DNA-binding protein 43.
2769mutation. Autophagic flux assays in hiPSC-derived
neurons from AD patients carrying PS1(A246E)
[287], PS1(Y115C) [288], PS1(M146I) [288], PS1-
(E120K) [289], or FAD-PS1 [290] mutations have
suggested a block in autophagy at the late stage
due to impaired autophagosome maturation. This
autophagic defect was characterized by an
increase in LC3-II, p62 and lysosomal load
[287e290], and disruption in lysosomal function[288], with the exception of PS1(E120K) mutant
neurons, in which, the elevation in LC3-II was not
associated with accumulation of p62 [289]. Similar
dysregulated autophagic and lysosomal pheno-
types were found in AD hiPSC-derived neurons
with APP mutations (V717I, trisomy 21, and
duplication) [288]. While impaired lysosomal func-
tionality could be a causative factor for the
autophagic block, increased activity of acid
Table 2. Defective autophagy phenotypes in non-hiPSC and patient-derived hiPSC models of neurodegenerative
diseases.
Neurodegenerative
disease
Mutant
protein
Autophagy phenotype in non-hiPSC
models
Autophagy phenotype in
patient-derived hiPSC
models
hiPSC-derived cell type
where
autophagy is studied
Alzheimer’s
disease (AD)
Presenilin-
1
Defective autophagy due to
impaired autophagosome
maturation [272e274]
via improper lysosomal
acidification and function
[273,274]
Defective autophagy
due to impaired
autophagosome
maturation
[287e290] possibly via
disruption in
lysosomal function
[288]; defective
autophagy due to
impaired
autophagosome
formation possibly
via TFEB inactivation [275]
AD hiPSC-derived neurons
[275,287,290] and cortical
neurons [288,289]
APP Perturbation in autophagy
(nature of the defect not clear) [272]
Defective autophagy due to
impaired autophagosome
maturation possibly via
disruption in lysosomal
function [288]
AD hiPSC-derived cortical
neurons [288]
Tauopathies,
including
frontotemporal
dementia (FTD)
Tau Defective autophagy
possibly due to impaired
autophagosome maturation
via disruption of axonal transport
[298,299]
Defective autophagy possibly
due to
impaired
autophagosome
maturation [308]
FTD hiPSC-derived
cortical neurons [308]
Parkinson’s
disease (PD)
a-synuclein Defective autophagy (by a-
synuclein gene
multiplication) due
to impaired autophagosome
formation [320,321] via ATG9
mislocalization [320] and
cytoplasmic retention of TFEB
[321]; defective CMA (by a-
synuclein point mutations A53T
or A30P) due to blockage
of substrate uptake [325]
Defective autophagy possibly
due to impaired
autophagosome
formation [338]
PD hiPSC-derived
dopaminergic neurons
[338]
P I N K 1 ,
Parkin
Defective mitophagy due
to impaired mitochondrial
targeting to autophagosomes
[316e319]
Not studied Not studied
LRRK2 Defective CMA due to
disruption of
the CMA translocation
complex [327]; Defective autophagy
possibly due to impaired
autophagosome maturation [328]
Defective
CMA [327,346];
Defective autophagy possibly
due to impaired
autophagosome
maturation [342,346]
PD hiPSC-derived
dopaminergic neurons
[327,342] and astrocytes
[346]
Amyotrophic lateral
sclerosis (ALS)
SOD1 Defective autophagy possibly due
to impaired autophagosome
maturation [352e354]
Defective autophagy (nature
of the
defect not clear) [387]
ALS hiPSC-derived motor
neurons [387]
TDP-43 Defective autophagy due to
impaired autophagosome
maturation possibly via
downregulation of dynactin 1 [356];
defective autophagy due to
impaired autophagosome formation
possibly via destabilization of ATG7
mRNA [355]
Not studied Not studied
FUS Defective autophagy due to
impaired autophagosome formation via
impairment in omegasome
formation and ATG9
recruitment [358]
Not studied Not studied
SQSTM1,
Optineurin,
Ubiquilin 2
Defective autophagy and
mitophagy due to impaired cargo
recruitment to
autophagosomes
Not studied Not studied
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Table 2 (continued)
Neurodegenerative
disease
Mutant
protein
Autophagy phenotype in non-hiPSC
models
Autophagy phenotype in
patient-derived hiPSC
models
hiPSC-derived cell type
where
autophagy is studied
[60,362e366], and disruption
of myosin VI-mediated
intracellular trafficking by optineurin [369]
TBK1 Defective mitophagy
possibly due to impaired
phosphorylation of
optineurin [367,368]
Defective autophagy
possibly due to
impaired autophagosome
formation [389]
ALS hiPSC-
derived motor
neurons [389]
CHMP2B Defective autophagy due to
impaired autophagosome
maturation via disruption of ESCRT
machinery [370,371]
Not studied Not studied
C9orf72 Defective autophagy
possibly due to impaired
autophagosome
formation via disruption of its interaction
with ULK1
and SMCR8/WDR41
complexes [373e376]
Defective autophagy
[373,390,391]
possibly due to
impaired
autophagosome
formation [373]
ALS/FTD hiPSC
derived-neurons [391],
motor neurons [390] and
iNeurons [373]
Huntington’s
disease (HD)
Huntingtin Defective autophagy due to
impaired recognition and
recruitment of autophagic cargo [401]
and dysfunction in axonal transport of
autophagosomes [402]
Perturbation in
autophagy (nature
of the defect
not clear) [409,410]
HD hiPSC-
derived neurons
[409] and GABAergic
medium spiny neurons
[410]
Multiple system
atrophy (MSA)
(Sporadic) Defective autophagy
(nature of the defect not
clear) [416,419,420]
Defective autophagy
possibly due
to impaired
autophagosome
maturation [423]
MSA hiPSC-derived
dopaminergic neurons
[423]
Gaucher disease
(GD)
GCase Defective autophagy
possibly due to impaired
autophagosome maturation
[426e428,432,433]
likely via disruption in
lysosomal function
[427,432]
Defective autophagy
due to impaired
autophagosome
maturation
[438,441e443] likely via
inefficient lysosomal
function [441]
GD iPSC-derived neurons
[441,443], dopaminergic
neurons [438,442] and
neuronal precursor cells
[443]
Saposin C Defective autophagy possibly due
to impaired autophagosome
maturation [426,430] likely via
inefficient cathepsin activity [430]
Not studied Not studied
Niemann-Pick type
C1 (NPC1)
disease
NPC1 Defective autophagy due to
impaired autophagosome
maturation [449,450] via disruption
in SNARE machinery [449],
reduction in sphingosine kinase
activity and VEGF levels [450]
Defective autophagy due to
impaired
autophagosome
maturation [450,454,455]
NPC1 hiPSC-
derived neurons
[450,454,455] and
hepatic cells [454]
Spinocerebellar
ataxia 3 (SCA3)
Ataxin-3 Defective autophagy due to
impaired autophagosome
formation [459,461] via
degradation of Beclin
1 [459], reduction in Sirtuin-1 [464]
Defective autophagy
(nature of the defect
not clear) [470]
SCA3 hiPSC-derived
neurons [470]
Spinal bulbar
muscular atrophy
(SBMA)
Androgen
receptor
Defective autophagy possibly due
to impaired autophagosome
maturation [474e476] via
suppression of TFEB
transactivation and downregulation
of autophagy-related genes [474]
Defective autophagy possibly
due to impaired
autophagosome maturation
[474] possibly via
downregulation of TFEB
target
genes [474]
SBMA hiPSC-derived
neuronal precursor cells
[474]
Charcot-Marie-
Tooth (CMT)
disease 2A
Mitofusin 2 Defective mitophagy due to
inefficient Parkin recruitment [491]
Increased autophagic flux
(mechanism not known) [493]
CMT2A hiPSC-derived
motor neurons [493]
Abbreviations e CHMP2B: charged multivesicular body protein 2B; CMA: chaperone-mediated autophagy; C9orf72: Chromosome 9
Open Reading Frame 72; ESCRT: Endosomal sorting complexes required for transport; FUS: Fused in sarcoma; GCase:
Glucocerebrosidase;; hiPSC: Human induced pluripotent stem cells; mTOR1: Mechanistic target of rapamycin complex1; SMCR8:
Smith-Magenis syndrome chromosome region, candidate 8; SNARE: Soluble N-ethylmaleimide-sensitive factor attachment protein
receptor; SOD1: superoxide dismutase 1; SQSTM1: Sequestosome 1; TBK1: TANK-binding kinase 1; TDP-43: TAR DNA-binding protein
43; TFEB: Transcription factor EB; ULK1: Unc-51 like autophagy activating kinase 1; VEGF: Vascular endothelial growth factor; WDR41:
WD repeat domain 41.
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Table 3. Therapeutic benefits with autophagy inducers in non-hiPSC in vivo models and in patient-derived hiPSC models
of neurodegenerative disorders.
Neurodegenerative
disease
Autophagy
inducer
Mechanism of autophagy induction Efficacy in non-hiPSC
in vivo models
Efficacy in patient-
derived hiPSC
models
A l z h e i m e r ’ s
disease (AD)
Rapamycin Induces autophagy via mTORC1
inhibition [88]
A D m i c e
[276,277,279,283,286]
Not tested
Trehalose Induces mTOR-independent autophagy
[91] via AMPK activation [92]
AD mice [280,284] Not tested
Carbamazepine Induces mTOR-independent autophagy
via reduction in inositol and IP3 [82]
AD mice [278,281] Not tested
Gypenoside XVII
(GP-17)
Induces autophagy via promoting TFEB
nuclear translocation [282]
AD mice [282] Not tested
Latrepirdine Induces autophagy via inhibition of
mTORC1 signaling [285]
AD mice [285] Not tested
Bexarotene Induces autophagy [291]; mechanism
not known
AD mice [496]a AD hiPSC-derived
neural stem cells
[291]
OM99-2 Induce autophagy possibly via inhibition
of b-secretase activity [288]
Not tested AD hiPSC-derived
cortical neurons [288]
Tauopathies,
including
frontotemporal
dementia (FTD)
Rapamycin Induces autophagy via mTORC1
inhibition [88]
Tauopathy mice [302e304],
Tauopathy Drosophila [300],
FTD mice [305]
Tauopathy hiPSC-
de r i v e d c o r t i c a l
neurons [308]
Trehalose Induces mTOR-independent autophagy
[91] via AMPK activation [92]
Tauopathy mice [306,307] FTD hiPSC-derived
neurons [310]
Carbamazepine Induces mTOR-independent autophagy
via reduction in inositol and IP3 [82]
FTD mice [305] Not tested
Parkinson’s
disease (PD)
Rapamycin Induces autophagy via mTORC1
inhibition [88]
PD mice [330e335] PD hiPSC-derived
dopaminergic
neurons [341]
Trehalose Induces mTOR-independent autophagy
[91] via AMPK activation [92]
PD mice [335] PD hiPSC-derived
dopaminergic
neurons [341]
6-Bio Induces autophagy via inhibition of
mTORC1 signaling [336]
PD mice [336] Not tested
Piperlongumine I n d u c e s a u t o p h a g y b y B c l - 2
phosphorylation and Bcl-2eBeclin1
dissociation [337]
PD mice [337] Not tested
GSK621 Induces autophagy via AMPK activation
[340]
Not tested PD hiPSC-derived
neurons [340]
A769662 Induces autophagy via AMPK activation
[340]
Not tested PD hiPSC-derived
neurons [340]
CMA activator Induces CMA via inhibition of RARa
signaling [497]
Not tested PD hiPSC-derived
dopaminergic
neurons and
astrocytes [346]
Amyotrophic lateral
sclerosis (ALS)
Rapamycin Induces autophagy via mTORC1
inhibition [88]
(Accelerated disease
phenotypes in ALS mice
[ 3 8 4 ] a n d A L S / F T D
Drosophila [356])
ALS hiPSC-derived
motor neurons [387]
Trehalose Induces mTOR-independent autophagy
[91] via AMPK activation [92]
ALS mice [379,380] Not tested
Bosutinib (SKI-
606)
Possibly induces autophagy via Src/c-
Abl inhibition [387]
Not tested ALS hiPSC-derived
motor neurons [387]
Fluphenazine Induces autophagy [195] possibly via
mTORC1 inhibition [498]
Not tested ALS/FTD h iPSC-
derived motor
neurons and
astrocytes [195]
Methotrimeprazine Induces autophagy [195]; mechanism
not known
Not tested ALS/FTD hiPSC-
derived motor
neurons and
astrocytes [195]
Huntington’s
disease (HD)
Rapamycin Induces autophagy via mTORC1
inhibition [88]
HD Drosophila [88], HD
zebrafish [83,85]
Not tested
T e m s i r o l i m u s
(CCI-779)
Induces autophagy via mTORC1
inhibition; rapamycin ester analogue [88]
HD mice [88] Not tested
Trehalose Induces mTOR-independent autophagy
[91] via AMPK activation [92]
HD mice [403]a Not tested
Rilmenidine Induces mTOR-independent autophagy
via reduction in cAMP [83]
HD mice [404] Not tested
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Table 3 (continued)
Neurodegenerative
disease
Autophagy
inducer
Mechanism of autophagy induction Efficacy in non-hiPSC
in vivo models
Efficacy in patient-
derived hiPSC
models
Clonidine Induces mTOR-independent autophagy
via reduction in cAMP [83]
HD Drosophila [83],
HD zebrafish [83]
Calpastatin Induces mTOR-independent autophagy
via calpain inhibition [83]
HD mice [405],
HD zebrafish [83]
Not tested
Felodipine Induces mTOR-independent autophagy
via reduction in cytosolic Ca2þ [94]
HD mice [94] Not tested
Verapamil Induces mTOR-independent autophagy
via reduction in cytosolic Ca2þ [83]
HD Drosophila [83],
HD zebrafish [83]
Not tested
Plerixafor
(AMD3100)
Induces autophagy via reduction in
ZBTB16 and increase in Atg14L [406]
HD mice [406] Not tested
SMER28 Induces mTOR-independent autophagy
[95]; mechanism not known
HD Drosophila [95] Not tested
L-NAME Induces mTOR-independent autophagy
via NOS inhibition [85]
HD Drosophila [85],
HD zebrafish [85]
Not tested
Valproic acid Induces mTOR-independent autophagy
via reduction in inositol and IP3 [82]
HD Drosophila [83] Not tested
AUTEN-67,
AUTEN-99
Induces autophagy via MTMR14
inhibition [407,408]
HD Drosophila [407,408] Not tested
EVP4593 Possibly affects autophagy via inhibition
of store-operated Ca2þ entry [410]
Not tested HD hiPSC-derived
neurons [410]
AST487 Possibly induces autophagy via HIPK3
inhibition [412]
Not tested HD hiPSC-derived
neurons [412]
Gaucher disease
(GD)
Rapamycin Induces autophagy via mTORC1
inhibition [87]
GD Drosophila [432] (Toxic in GD iPSC-
der ived neurons)
[441]
Torin 1 Induces autophagy via ATP-competitive
inhibition of mTORC1 inhibition [90]
Not tested GD iPSC-der ived
neurons [443]
Niemann-Pick type
C1 (NPC1)
disease
Rapamycin Induces autophagy via mTORC1
inhibition [87]
Not tested NPC1 hiPSC-derived
neurons and hepatic
cells [454]
Carbamazepine Induces mTOR-independent autophagy
via reduction in inositol and IP3 [82]
Not tested NPC1 hiPSC-derived
neurons and hepatic
cells [454]
Trehalose Induces mTOR-independent autophagy
[91] via AMPK activation [92]
Not tested NPC1 hiPSC-derived
neurons [454]
Verapamil Induces mTOR-independent autophagy
via reduction in cytosolic Ca2þ [83]
Not tested NPC1 hiPSC-derived
neurons [454]
BRD5631,
BRD2716,
BRD34009
Induces mTOR-independent autophagy;
mechanism not known [456]
Not tested NPC1 hiPSC-derived
neurons [456]
MbCD Induces autophagy via mTORC1
inhibition and AMPK activation [455]
Not tested NPC1 hiPSC-derived
neurons [455]
Spinocerebellar
ataxia 3 (SCA3)
Temsirolimus
(CCI-779)
Induces autophagy via mTORC1
inhibition; rapamycin ester analogue [88]
SCA3 mice [466] Not tested
Calpeptin Induces mTOR-independent autophagy
via calpain inhibition [83]
SCA3 zebrafish [467] Not tested
Lithium chloride Induces mTOR-independent autophagy
via inhibition of IMPase and reduction in
inositol and IP3 [82]
SCA3 Drosophila [468] Not tested
Sodium valproate Induces mTOR-independent autophagy
via reduction in inositol and IP3 [82]
SCA3 Drosophila [469] Not tested
Abbreviations e AMPK: 50 adenosine monophosphate-activated protein kinase; Atg: Autophagy-related; ATP: Adenosine triphosphate;
Bcl-2: B-cell lymphoma 2; Ca2þ: Calcium; cAMP: 30, 5’ -cyclic adenosine monophosphate; CMA: Chaperone-mediated autophagy; IP3:
Inositol 1,4,5-triphosphahe; HIPK3: Homeodomain interacting protein kinase 3; hiPSC: Human induced pluripotent stem cells; MTMR14:
Myotubularin-related protein 14; mTORC1: Mechanistic target of rapamycin complex1; NOS: Nitric oxide synthase; RARa: Retinoic acid
receptor a; SMER: Small molecule enhancer of rapamycin; TFEB: Transcription factor EB; ZBTB16: Zinc finger and BTB domain-
containing protein 16.
a These studies do not show the autophagy-inducing properties of the compounds for the therapeutic effects in vivo.
2773sphingomyelinase (ASM) in hiPSC-derived FAD-
PS1 neurons has also been shown to block
autophagic flux possibly via lysosomal depletion
[290].However, studies in hiPSC-derived neurons from
AD patients carrying PS1(M146L) mutation or
hiPSC-derived neurons with PS1 depletion [275],
and in hiPSC-derived neural stem cells (NSCs) with
2774PS1(M146L) knock-in [291] or PSEN1 gene knock-
out [292], have reported reduction in autophago-
somes and LC3-II levels [275,291,292], low TFEB
expression [291,292], and attenuation in CLEAR
gene network activity [275]. These data indicate a
possible suppression of autophagy at an early stage
due to impaired autophagosome formation. This
apparent discrepancy in the nature of autophagic
defect could be due to the fact that loss of PS1 in
hiPSC-derived neurons might be perturbing autop-
hagy via different mechanisms. For example, PS1/2
deficiency has been suggested to lower nuclear
Ca2þ and CaMKIV/pCREB signaling, resulting in the
reduction of sestrin2 (a stress-inducible protein) that
led to excessive lysosomal tethering of mTORC1,
and consequently, dysregulation of mTORC1 activ-
ity and dynamics. This caused hyperphosphorylation
and inactivation of TFEB and subsequent suppres-
sion of the CLEAR gene network activity, thereby
decreasing LC3 expression [275]. An additional
factor could be high levels of the amino acid,
homocysteine, which is associated with an
increased risk of developing AD [293]. Treatment
of hiPSC-derived neurons with homocysteine
increased mTORC1 activity and suppressed TFEB-
mediated CLEAR gene network activity, thereby
preventing autophagosome formation and reducing
autophagic flux that caused accumulation of Ab and
phosphorylated tau filaments [294].
Defective autophagy is likely to retard mitophagy,
which has been demonstrated in hiPSC-derived
PS1(A246E) neurons [287] and PS1(M146L) NSCs
[291]. Of biomedical relevance, induction of autop-
hagy promoted Ab clearance and improved neuronal
viability in hiPSC-derived neurons, such as with
rapamycin and Tat-Beclin 1 treatment in hyperho-
mocysteinemic conditions [294]. Bexarotene could
also stimulate autophagic flux and rescue the
autophagy and mitophagy defects in hiPSC-derived
PS1(M146L) NSCs [291]. Interestingly, inhibition of
b-secretase activity with OM99-2 corrected the
autophagic defects by promoting the degradative
capability of autophagy and reduced Ab levels in
multiple hiPSC-derived neurons from AD patients
with the various APP or PS1 mutations [288].
Overall, a wide range of PSEN1 mutations has
shown a blockage in autophagic flux due to impaired
autophagosome maturation in hiPSC-derived neu-
rons, consistent with the results seen in other cellular
and animal models. This autophagic defect is likely
due to impairment in lysosomal function. On the
contrary, complete loss of PS1/2 or the PS1(M146L)
mutation caused inhibition of autophagosome for-
mation in hiPSC-derived neurons, and this might be
due to specific effects on the protein function.
Further studies are required to assess whether
autophagy inducers would have a positive impact
on neuronal viability in multiple AD hiPSC modelssince autophagy induction had beneficial effects in
cellular and animal models of AD.
Tauopathies, including frontotemporal dementia
Another key hallmark of AD is the formation of
intracellular neurofibrillary tangles made of hyper-
phosphorylated microtubule-associated tau protein,
which is encoded by the MAPT gene. Accumulation
of mutant tau is characteristic of tauopathies,
including frontotemporal dementia (FTD) [295].
FTD affects the frontal and temporal lobes of the
brain and is also associated with the accumulation of
TAR DNA-binding protein 43 (TDP-43) [296]. In
addition, mutations in GRN encoding for progranulin
cause FTD, while complete loss of this gene causes
a lysosomal storage disorder (LSD) called neuronal
ceroid lipofuscinosis (NCL) [297]. Mutant tau, which
contributes to neuronal cell death, is thought to
impair autophagosome maturation. Studies in FTD
Drosophila and mouse models have shown that
mutant tau deregulated the retrograde axonal trans-
port on the microtubule and prevented the fusion of
autophagosomes with lysosomes [298,299]. On the
other hand, mutant tau could undergo autophagic
degradation [300,301]. The pharmacological induc-
tion of autophagy was shown to rescue the disease
pathogenesis in tauopathy and FTD mouse models.
Therapeutic benefits, including a reduction in tau
tangles, have been demonstrated with rapamycin in
mutant tau mice [302e304], mutant TDP-43 mice
[305], and mutant tau Drosophila model [300], with
carbamazepine in mutant TDP-43 mice [305], and
with trehalose in mutant tau mice [306,307].
Autophagy has been studied in tauopathy hiPSC
lines, such as 19-L3-RC3, 19-L5-RC6, and Tau6-1-
RC2, which were generated from patients carrying
the tau(A152T) mutation that increases the risk of FTD
[308]. Tau levels, as well as phosphorylation at AT8
and AT108, were increased in tau(A152T) hiPSC-
derived cortical neurons compared to the control
neurons, and their distribution was predominantly
somatodendritic; consistent with what was seen in
tauopathies and AD. The autophagy (LC3-II,
ATG12-ATG5) and lysosomal (LAMP1, LAMP2a)
markers were upregulated in tau(A152T) neurons
[308], suggesting a possible induction of autophagy.
However, the autophagy substrate p62, as well as
polyubiquitinated proteins, were also accumulated in
these neurons [308], indicating that autophagic flux
might be retarded, and this could be due to impaired
autophagosome maturation causing an increase in
autophagosomes (LC3-II). Nonetheless, induction of
autophagy with rapamycin in tau(A152T) neurons
reduced the cellular load of mutant tau and improved
cell viability in the presence of external stressors like
mitochondrial toxins, proteasome inhibitors, and
Ab42; effects that were also seen with CRISPR/
2775Cas9-mediated tau gene disruption for reducing the
mutant protein level [308]. Another hiPSC tauopathy
model has been developed by transducing tau(P310L)
mutation into neural progenitor (NP) cells that were
differentiated from hiPSCs derived from healthy
donors [309]. Since spontaneous tau aggregation
was not observed in NP-derived cortical neurons
expressing tau(P310L), this phenotype was enforced
by seeding the cells with mutant tau preformed fibrils
(K18). Consistent with other studies, autophagy
inducers, such as rapamycin and trehalose, reduced
the levels of tau aggregates and the phosphorylation
at the AT8 site that promotes their aggregation [309].
Trehalose also increased autophagosome formation
and progranulin expression in hiPSC-derived neu-
rons carrying GRN mutations causative of progra-
nulin haploinsufficiency [310].
Although the studies in hiPSC tauopathy models
do not clearly define the status of autophagic flux for
which further analysis is required, it might be
possible that this is affected due to impaired
autophagosome maturation, as reported in non-
hiPSC models. Importantly, autophagy inducers
rescued the disease phenotypes in both mouse
and hiPSC-derived neuronal models, suggesting
that autophagy induction could be beneficial in
tauopathies.
Parkinson’s disease
Parkinson’s disease (PD) is a progressive neuro-
degenerative disorder of the central nervous system,
characterized by cognitive deterioration and motor
deficits. The hallmark of PD is the presence of
intracellular inclusions of abnormal protein aggre-
gates called Lewy bodies [311]. PD is a multigenic
disorder, in which, the genes that are commonly
mutated encode for Parkin, PINK1 (PTEN induced
putative kinase 1), a-synuclein, and LRRK2 (leucine-
rich repeat kinase 2). These and other PD-asso-
ciated mutant proteins have been shown to cause
dysfunction of autophagy and mitophagy [312e314].
Extensive studies have elucidated the role of wild-
type PINK1 and Parkin in regulating mitophagy for
the maintenance of mitochondrial quality control.
Selective mitophagy of damaged mitochondria is
initiated by PINK1 stabilization on the outer mito-
chondrial membrane (OMM), where it phosphory-
lates and activates the E3 ubiquitin ligase Parkin,
which ubiquitinates OMM proteins for enabling
mitochondrial targeting to the autophagy pathway
[313,315]. This process was disrupted by the PD-
associated mutations in PINK1 and Parkin that lead
to mitochondrial dysfunction, mitochondrial DNA
mutations, and oxidative stress [316e319]. On the
other hand, the overall autophagy process was
impaired by mutant a-synuclein in multiple ways.
Accumulation of a-synuclein, such as occurring
during its gene multiplication, has been shown tosuppress autophagosome biogenesis via ATG9
mislocalization [320] and cytoplasmic retention of
TFEB [321]. However, the Lewy bodies comprising
of a-synuclein inclusions retarded autophagosome
maturation without causing lysosomal malfunction
[322]. Other PD-associated mutant proteins, such as
VPS35, ATP13A2, and STY11, have also been
reported to impair autophagy [323,324]. Further-
more, a-synuclein(A53T) and a-synuclein(A30P) point
mutants could prevent chaperone-mediated autop-
hagy (CMA), a process distinct from macroauto-
phagy involving protein translocation across the
lysosomal membrane [325,326]. In addition,
LRRK2 mutants, including LRRK2(G2019S) also
impaired CMA that could compromise the clearance
of mutant a-synuclein [327], as well as possibly
impaired autophagosome maturation [328]. While
autophagic dysfunction occurs in PD via multiple
mechanisms, pharmacological induction of autop-
hagy could facilitate mutant a-synuclein clearance
[329] in vitro and in vivo, and exert beneficial effects
in animal models of PD. Stimulating autophagy with
rapamycin, either alone [330e334] or in combination
with trehalose [335], as well as with other autophagy-
inducing compounds like 6-Bio [336] and piperlon-
gumine [337], demonstrated neuroprotective effects
and improved motor functions in toxin-induced or a-
synuclein transgenic mouse models of PD.
Multiple hiPSC lines from PD patients carrying
different gene mutations have been utilized to study
autophagy. Dopaminergic neurons generated from
PD hiPSCs with a-synuclein mutations, such as
SNCA(A53T) or SNCA(triplication), exhibited a reduction
in LC3-II levels that were associated with an
elevation in p62 levels in some of the lines;
suggesting a possible impairment in autophago-
some formation, as seen in cell models [338]. These
mutant a-synuclein neurons also showed dysfunc-
tion in mitochondrial bioenergetics and lipid home-
ostasis [338]. Furthermore, in the PARK10
susceptibility locus associated with late-onset PD,
a gene encoding for USP24 (ubiquitin specific
peptidase 24) that was elevated in the brain of
idiopathic PD patients has been suggested to
suppress autophagy, since knockdown of USP24
induced autophagic flux in hiPSC-derived dopami-
nergic neurons [339]. However, consistent with a-
synuclein inclusions preventing autophagosome
maturation in cell models, the treatment of hiPSC-
derived neurons with exogenous a-synuclein pre-
formed fibrils, but not monomeric a-synuclein,
caused time-dependent accumulation of a-synuclein
inclusions, autophagosomes, and p62 [340]. Induc-
tion of autophagy with AMPK activators, such as
GSK621 and A769662, restored the autophagic flux
and enhanced the clearance of a-synuclein inclu-
sions [340]. Additionally, in hiPSC-derived dopami-
nergic neurons, where mitochondria were
compromised by rotenone treatment, inducing
2776autophagy with rapamycin and trehalose rescued
mitochondrial neurotoxicity and dysfunction [341].
Defects in CMA have been reported in hiPSC-
derived dopaminergic neurons of PD patients with
LRRK2(G2019S), where abnormal accumulation of a-
synuclein probably occurred due to its impaired CMA
clearance [327]; consistent with the findings from
noniPSC experimental systems. Additionally, dopa-
minergic neurons generated from multiple hiPSC
lines with familial PD with LRRK2(G2019S) mutation or
idiopathic PD, also exhibiting elevated a-synuclein
levels, showed impairment in autophagic flux due to
defective autophagosome maturation, as evident
from accumulation of LC3-II and p62, and reduction
in the colocalization between autophagosomes and
lysosomes, as well as increased mitochondrial
fragmentation [342e344]. A similar autophagic
block was found in PD hiPSC-derived dopaminergic
neurons with LRRK2(I2020T) mutation [345]. In
LRRK2(G2019S) neurons, mutant LRRK2-mediated
phosphorylation of leucyl-tRNA synthetase was
suggested to impair autophagy [328], whereas the
increased activity of RAC1 (Rac family small
GTPase 1) was shown to rescue the autophagy
defects, a-synuclein accumulation, and cell death
[343]. Similar to the neuronal phenotypes, PD
hiPSC-derived astrocytes with LRRK2(G2019S) muta-
tion exhibited impaired CMA, autophagic block, and
accumulation of a-synuclein [346]. Interestingly, a
contribution of the astrocytes to noncell-autonomous
neurodegeneration in PD has also been suggested.
LRRK2(G2019S) mutant astrocytes promoted neuro-
degenerative features like shortened neurites, a-
synuclein accumulation, and decreased viability in
control iPSC-derived dopaminergic neurons during
coculture; and conversely, control astrocytes par-
tially rescued these phenotypes when cocultured
with LRRK2(G2019S) mutant neurons [346]. Tagging
the endogenous a-synuclein with a FLAG peptide in
control astrocytes resulted in the accumulation of
FLAG-tagged a-synuclein in mutant dopaminergic
neurons during the coculture, suggesting a direct
transfer of astrocytic a-synuclein to the neurons
[346]. Enhancing the lysosomal activity with a CMA
activator (CA) decreased a-synuclein levels in
LRRK2(G2019S) astrocytes, and also partially pre-
vented the neurodegenerative features in control
dopaminergic neurons during coculture [346].
PD is a multigenic disorder, and thus, the nature of
the autophagy defects and the underlying mechan-
isms vary depending on the gene mutations.
Chemical induction of autophagy has been shown
to be beneficial in cellular and animal models of PD,
but the cytoprotective effects of autophagy inducers
in hiPSC-derived dopaminergic neurons from PD
patients remain to be thoroughly investigated.Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal
neurodegenerative disorder, primarily sporadic but
also familial, in which the motor neurons, located in
the motor cortex, brainstem, and spinal cord, are
affected that lead to muscle weakness and progres-
sive loss of voluntary muscle movement [347].
Certain clinical symptoms, disease phenotypes,
and genetic causes are overlapping between ALS
and FTD [348]. Several genes associated with ALS
cause autophagy dysfunction or encode for mis-
folded proteins that can undergo autophagic degra-
dation [349]. Mutations in genes encoding for SOD1
(superoxide dismutase 1), TDP-43 (TAR DNA-
binding protein 43), and FUS (fused in sarcoma)
lead to accumulation of misfolded proteins that can
be degraded by autophagy, although these mutant
proteins could dysregulate this process [349,350].
Mutant SOD1(G93A) has been suggested to suppress
autophagy and mitophagy via a reduction in TFEB,
Beclin 1, or lysosomes [351,352], and possibly
cause an autophagic block in transgenic mice, as
evident from the accumulation of autophagosomes
and autophagy substrates [352e354]. Mutation or
loss of TDP-43 has also been shown to impair
autophagy via its inability to bind and stabilize ATG7
mRNA and prevent autophagosome maturation via
downregulation of dynactin 1 [355,356]. However,
mutant FUS, which accumulates in stress granules
to be degraded via autophagy [357], prevented
autophagosome biogenesis, possibly due to impair-
ment in omegasome formation and recruitment of
ATG9 to the growing autophagosomes [358]. Other
ALS-associated genes include SQSTM1 [359],
OPTN [360], and UBQLN2 [361] that encode for
the autophagy receptors p62, optineurin, and ubi-
quilin 2, respectively. Disease-causing mutations in
these autophagy receptors decreased autophagic
flux and mitophagy via impairment in cargo recruit-
ment to the autophagosomes, thereby preventing
the clearance of SOD1, TDP-43, and damaged
mitochondria [60,362e366]. ALS-associated muta-
tions in TBK1 (TANK-binding kinase 1), which
normally phosphorylates optineurin to promote
mitophagy, also caused inefficient mitochondrial
clearance [367,368]. Additionally, ALS-linked muta-
tions in optineurin disrupted myosin VI-mediated
autophagosome maturation, causing a block in
autophagic flux [369]. Defective autophagosome
maturation also resulted from ALS-associated muta-
tions in CHMP2B (charged multivesicular body
protein 2B) via disruption of the ESCRT (endosomal
sorting complexes required for transport) machinery
[370,371], which plays a role in the late stages of
autophagy, as well as in autophagosome closure
2777[372]. One of the most common causes of ALS is the
hexanucleotide repeat expansion in a noncoding
region of C9orf72 (Chromosome 9 Open Reading
Frame 72) gene, which has been shown to regulate
autophagy. A role of C9orf72 in autophagosome
formation and maturation has been implicated via its
interaction with ULK1 and Rab1a [373,374], and also
via its GEF (guanine nucleotide exchange factor)
effector activity for Rab GTPases through a complex
formation with SMCR8 (Smith-Magenis syndrome
chromosome region, candidate 8) and WDR41 (WD
repeat domain 41) [375,376]. Accordingly, depletion
or loss of C9orf72 inhibited autophagy and
decreased autophagic flux in mammalian cell lines,
primary mouse and rat neurons, and in vivo in
knockout mice [373e376], as evident from reduction
in autophagosomes and accumulation of autophagy
substrates; whereas a contrary study suggested
enhanced autophagic flux in C9orf72 knockout mice
[377]. However, an autophagic block was apparent
in C9ALS/FTD patient-derived fibroblasts with
C9orf72 hexanucleotide repeat expansions due to
the accumulation of both LC3-II and p62 [378].
The pharmacological induction of autophagy
showed conflicting outcomes in ALS mice. While
trehalose and lithium ameliorated the disease
phenotypes in SOD1 (G93A) transgenic mice
[379e381], other studies in these mice showed no
therapeutic benefits with lithium [382,383], and even
acceleration of the disease progression by rapamy-
cin and rilmenidine in SOD1(G93A) mouse and TDP-
43-depleted Drosophilamodels [356,384,385]. How-
ever, autophagy activation in cell models with
rapamycin [357], rilmenidine [385], fluphenazine
[195], methotrimeprazine [195], and berberine (a
natural herb) [386] was neuroprotective by enhan-
cing the clearance of misfolded TDP-43 and SOD1,
and FUS-positive stress granules.
Several studies utilizing ALS patient-derived
hiPSC models carrying various ALS-linked gene
mutations have demonstrated autophagy defects.
Reduction in autophagic flux was shown in SOD1-
(L144FVX) hiPSC-derived motor neurons where induc-
tion of autophagy with rapamycin or the Src/c-Abl
inhibitor, bosutinib, reduced misfolded SOD1 levels
and improved cell viability [387]. Similarly, induction
of autophagy by methotrimeprazine and fluphena-
zine was attributed to their neuroprotective effects in
motor neurons and astrocytes derived from ALS
hiPSCs carrying a pathogenic TARDBP (M337V) muta-
tion encoding for mutant TDP-43 [195]. Likewise,
mTOR inhibitors like rapamycin and torkinib, as well
as certain other antipsychotic and antidepressant
drugs known to induce autophagy, reduced FUS-
associated stress granules in genome-edited
hiPSCs, and hiPSC-derived neurons expressing
EGFP-tagged FUS(P525L), where rapamycin also
improved neuronal survival [388]. Autophagic flux
was also retarded, possibly due to inhibition ofautophagosome formation, in motor neurons gener-
ated from various ALS hiPSC lines carrying different
heterozygous TBK1 mutations, where an accumula-
tion of cytosolic p62 aggregates was found [389].
Likewise, cortical and motor neurons generated from
multiple ALS hiPSC lines with C9orf72 hexanucleo-
tide repeat expansions exhibited a reduction in
autophagic flux, resulting in accumulation of LC3-II,
p62, and stress granules [390,391]. Autophagosome
formation was markedly suppressed in C9ALS/FTD
patient-derived induced neurons (iNeurons) with
C9orf72 expansion mutation [373]; consistent with
the autophagy phenotype in C9orf72 depletion
cellular models. Furthermore, elevated levels of the
insoluble fraction of optineurin were found in motor
neurons derived from ALS hiPSCs with SOD1, TDP-
43, or C9orf72 mutations [392]. Like in PD, astro-
cytes have been suggested contributing to noncell-
autonomous neurodegeneration in ALS [393,394].
Conditioned medium from hiPSC-derived astrocytes
with C9orf72 repeat expansions was toxic, specifi-
cally on hiPSC-derived motor neurons, and also
impaired autophagic flux in mammalian cells that
could be rescued by rapamycin [395].
Multiple genes associated with ALS encode
mutant proteins that differentially affect autophagy.
Some of the autophagic defects have been char-
acterized in ALS patient hiPSC-derived motor
neurons. However, it is not entirely clear whether
autophagy induction would be beneficial in ALS.
Although certain autophagy inducers were cytopro-
tective in cell and hiPSC models, some others had
deleterious effects in vivo in transgenic models.
Further studies are warranted using mTOR-inde-
pendent autophagy inducers, which are considered
relatively safer for inducing autophagy compared to
using mTOR inhibitors.
Huntington’s disease
Huntington’s disease (HD) is an autosomal-
dominant, monogenic neurodegenerative disorder
characterized by motor, cognitive, and psychiatric
impairments. HD is caused by the excessive
expansion of the CAG trinucleotide repeat in the
HTT gene, encoding for the protein huntingtin, in
which, the addition of the N-terminal polyglutamine
repeats makes the protein aggregation-prone and
cytotoxic [396]. Mutant huntingtin is an established
autophagy substrate [397,398], and its autophagic
clearance could be conformation-dependent [397],
while its wild-type counterpart acts as a scaffold for
recruiting autophagic proteins during aggrephagy
and mitophagy [399,400]. Autophagy is impaired in
HD, characterized by an accumulation of autopha-
gosomes, which is considered primarily due to
failure in the recognition and recruitment of autop-
hagic cargo [401], as well as defective axonal
transport of the autophagosomes [402]. Of
2778biomedical relevance, induction of autophagy is a
promising treatment strategy in HD, as evident from
the extensive studies in transgenic in vivo models,
where chemical autophagy inducers ameliorated the
disease phenotypes. These include rapamycin [88],
trehalose [403], rilmenidine [404], calpastatin [405],
AMD3100 (G-protein-coupled receptor antagonist)
[406], and felodipine [94] in HD mice; and SMER28
[95], verapamil [83], valproic acid [83], L-NAME [85],
AUTEN-67 [407], and AUTEN-99 [408] in HD
Drosophila models, amongst others.
Perturbations in autophagy have been observed in
a few HD patient-derived hiPSC models. The HTT
mutation did not affect the reprogramming or
neuronal differentiation, and the CAG repeat num-
bers were stable during these processes [409].
Accumulation of autophagosomes and lysosomes
were found in neurons differentiated from HD hiPSC
lines, namely HD-iPShom 4F-1 (42/44 CAG repeats),
HD-iPShet 3F-1 (17/45 CAG repeats) [409], and
iPSHD22 (47/16 CAG repeats) [410], as well as
increased cytoplasmic vacuolation in astrocytes
generated from HD iPSC line, D-HD-iPSC (109
CAG repeats) [411]. In addition, increased Ca2þ
entry via store-operated channels (SOC) was seen
in HD iPSC (iPSHD22)-derived neurons, an effect
consistent with Ca2þ excitotoxicity in HD animal
models, where EVP4593 (SOC Ca2þ channel
inhibitor) improved Ca2þ homeostasis that was
associated with a reduction in autophagosomes
[410]. Moreover, since mutant huntingtin is an
autophagy substrate, its autophagic degradation
might be regulated by kinases, such as HIPK3
(homeodomain interacting protein kinase 3) [412],
which inhibits autophagy via DAXX [413]. Knock-
down of HIPK3 increased autophagic flux and
lowered mutant huntingtin load in HD iPSC (iPSC-
HDQ47)-derived neurons, and this reduction of
mutant huntingtin levels was also achieved with the
HIPK3 inhibitor, AST487 [412].
The autophagy defect and the therapeutic benefits
of autophagy inducers have been robustly demon-
strated in mammalian cell and animal models of HD
[7,81,88,108,401]. However, the hiPSC-related stu-
dies did not portray a clear picture of the nature of the
autophagy dysfunction due to a lack of rigorous
analysis, although the accumulation of autophago-
somes was a common feature. Extensive analysis of
autophagic flux and the therapeutic evaluation of
established autophagy inducers would be important
next steps to undertake in HD hiPSC-derived
neurons to aid clinical translation.
Multiple system atrophy
Multiple system atrophy (MSA) is a sporadic adult-
onset neurodegenerative disorder characterized by
autonomic dysfunction, parkinsonism, and ataxia.
The hallmark of MSA is the presence of glialcytoplasmic inclusions (GCIs), primarily made of a-
synuclein, in oligodendrocytes, and thus, MSA falls
under the spectrum of synucleinopathies [414,415].
As in other neurodegenerative disorders, the autop-
hagy pathway is affected in MSA. Neuropathological
studies in MSA patient brain samples have shown
elevation in LC3-II, autophagy receptors (p62 and
NBR1), and AMBRA1 (mediator of autophagy
initiation) that colocalized with the GCIs [416e419].
Transgenic mice with oligodendrocyte-specific
expression of human a-synuclein (haSYN) under
proteolipid protein (PLP) gene promoter (PLP-
haSYN mice), which exhibits MSA-like GCIs, also
revealed accumulation of LC3-II [420]. However, the
levels of GABARAPs were reduced in the cerebel-
lum of MSA patient brains, where they did not
localize to the GCIs [419]. Moreover, TFEB was
decreased in MSA patient brains, whereas oligoden-
droglial overexpression of TFEB, but not neuronal,
exerted neuroprotective effects, and enhanced
autophagic flux in PLP-haSYN mouse model [421].
Furthermore, impaired mitophagy and mitochondrial
function have been reported in MSA patient fibro-
blasts [422]. Although the precise nature of the
autophagy defect is unclear, it is possible that the
dysfunction of autophagy could cause oligodendro-
glial accumulation of a-synuclein that might con-
t r i b u t e t o t he f o rma t i on o f GC I s and
neurodegeneration in MSA.
A study in MSA patient-derived hiPSC models
reported impairment in autophagy and mitochondrial
function in hiPSC-derived dopaminergic neurons
[423]. In these MSA neurons, the levels of LC3-II,
p62, and mitochondrial load were increased, indica-
tive of a block in autophagic flux possibly at the late
stage of autophagy, while the activities of the
mitochondrial respiratory chain complexes were
decreased [423]. Further studies are needed to
understand how autophagy is affected in MSA and
the mechanism underlying this defect, and impor-
tantly, whether pharmacological inducers of autop-
hagy would be beneficial.
Gaucher disease
Gaucher disease (GD) is an autosomal recessive
disease that manifests neurological, splenic, and
hepatic dysfunctions. It is one of the most prevalent
lysosomal storage disorder (LSD) caused by muta-
tions in the GBA1 gene, encoding for glucocerebro-
sidase (GCase), and in rare cases by mutations in
the PSAP gene, leading to a deficiency of the GCase
activator, saposin C [424,425]. The GCase enzyme
normally hydrolyzes glucosylceramide, and the
lysosomal accumulation of glucosylceramide and
glucosylsphingosine in GD is suggested to dereg-
ulate the later stages of the autophagic process.
Consistent with the features of a block in autophagic
flux, accumulation of autophagosomes and
2779autophagy substrates accompanied by dysfunc-
tional cathepsin activity, impaired mitophagy, and
mitochondrial function have been reported in patient
fibroblasts, and in Drosophila and mouse models of
GD with GCase or saposin C deficiency [425e434].
Interestingly, GD patients carrying GBA1 mutations
are prone to neurodegeneration with a higher risk of
acquiring Parkinson’s disease (PD) [429,435]
because defective autophagy underlying GCase
deficiency could accumulate a-synuclein, while
upregulation of a-synuclein in idiopathic PD might
disrupt GCase activity [436e439]. This pathogenic
link could be rescued by enhancing autophagy with
rapamycin or C2-ceramide that suppressed mutant
GBA-induced a-synuclein accumulation in cell mod-
els [437,440]. Moreover, the induction of autophagy
with rapamycin enhanced autophagosome forma-
tion in saposin C-deficient patient fibroblasts [430],
as well as rescued the disease phenotypes and
extended the life span in a dGBA1-deficient Droso-
phila model of GD [432].
Multiple studies have utilized GD patient-derived
hiPSC models to gain insights into the disease
mechanisms, including autophagy. In neurons differ-
entiated from several GD iPSC lines with GBA1
mutations, defective autophagic flux due to impaired
autophagosome maturation and lysosomal dysfunc-
tion was evident from the accumulation of autopha-
gosomes and autophagy substrates, such as p62,
reduced autophagosomeelysosome fusion and
inefficient activity of lysosomal enzymes like cathe-
psins [438,441e443]. Increased mTORC1 activity,
downregulation of TFEB, and depletion of lyso-
somes were reported in neuropathic GD iPSC-
derived neurons and neuronal precursor cells
(NPCs) where the reduction in lysosomal compart-
ments could contribute to ineffective autophago-
some clearance [441,443]. In these GD neurons,
treatment with recombinant GCase rescued the
lysosomal and autophagic defects, effects that
were augmented when coupled with TFEB over-
expression [441]. Additionally, pharmacological inhi-
bition of glucosylceramide synthase with the
compound GZ-161, which prevents the production
of glucosylceramide, rescued mTORC1 hyperacti-
vation in GD NPCs, thereby suggesting a possible
role of lipid substrate accumulation in influencing
mTORC1 activity [443]. In contrast, other studies
found increase in the number and size of lysosomes
in dopaminergic neurons generated from GD or PD
patients with GBA1 mutations [438,442]. These
GBA1 mutant dopaminergic neurons exhibited a
reduction in GCase activity, as well as the accumu-
lation of glucosylceramide and a-synuclein, thus
highlighting the pathogenic link between GD and PD
[436,438,442]. Multiple cellular phenotypes were
shown in these mutant cells, including abnormal
lipid profiles, ER stress [442], increased neuronal
calcium-binding protein 2 (NECAB2), elevated cyto-solic Ca2þ, and dysfunctional Ca2þ homeostasis
[438] that could also affect autophagic flux
[83,84,444]. In addition, accumulation of a-synuclein
could also impair lysosomal function by disrupting
the trafficking and activity of the hydrolase, as
demonstrated in GD and PD iPSC-derived neurons,
where overexpression of Rab1a rescued these
cellular phenotypes [445].
Surprisingly, the induction of autophagy via mTOR
inhibition with rapamycin was found to be toxic in GD
iPSC-derived neurons [441]; however, Torin1 was
shown to induce TFEB nuclear translocation and
improve autophagic clearance [443]. More studies
are required to extensively evaluate the therapeutic
potential of mTOR-dependent and mTOR-indepen-
dent autophagy inducers in order to understand
whether enhancing autophagy is beneficial in GD.
Nonetheless, a block in autophagic flux has been a
consistent feature in animal and iPSC models of GD.
Niemann-Pick type C disease
Niemann-Pick type C (NPC) disease is a rare,
autosomal recessive LSD characterized by neuro-
degeneration and hepatosplenomegaly, and is
associated with mutations predominantly in the
NPC1 gene (~95%) causing NPC1 disease or in
the NPC2 gene (~5%) causing NPC2 disease [446].
These genes encode NPC1 and NPC2 proteins,
which respectively are lysosomal cholesterol trans-
porter and lysosomal glycoprotein that play a role in
the transport of cholesterol from late endosomes and
lysosomes. Mutations in these genes lead to
abnormal accumulation of unesterified cholesterol
and other lipids like sphingolipids in the brain, liver,
and spleen [447,448]. As in other LSDs [104],
autophagic flux is retarded due to defective autop-
hagosome maturation, as shown in mutant mouse
and human cellular models of NPC1 and NPC2
disease, which are also associated with defective
mitophagy and mitochondrial function [449e452].
Multiple mechanisms shown for dysregulated autop-
hagy in NPC1 disease include disruption of SNARE
complex formation between autophagosomes and
late endosomal/lysosomal compartments involving
Syntaxin-17 and VAMP8 to prevent autophagosome
maturation [449], accumulation of sphingosine aris-
ing from diminished activity of sphingosine kinase
and decreased levels of vascular endothelial growth
f a c t o r ( V E G F ) t o p r e v e n t
autophagosomeelysosome fusion [450], and reduc-
tion in lysosomal Ca2þ stores [453]. Despite a block
in the multistep route of autophagosome maturation,
autophagy inducers improved autophagic flux in
Npc1 mutant mouse cells by facilitating direct
autophagosomeelysosome fusion (bypass mechan-
ism), which consequently also increased cell survi-
val but did not reduce the cholesterol load [449].
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due to impaired autophagosome maturation, char-
acterized by accumulation of autophagosomes and
autophagy substrates like p62, was found in neurons
and hepatic cells differentiated from multiple NPC1
hiPSC lines that also exhibited elevation in choles-
terol [450,454,455]. Genetic correction of a disease-
causing NPC1(I1061T) mutation rescued the cellular
phenotypes of defective autophagy and cholesterol
accumulation in these NPC1 hiPSC-derived cells
[454]. Autophagic block associated with impaired
mitophagy and mitochondrial fragmentation was
also found in neurons derived from hESCs with
shRNA-mediated NPC1 knockdown [452]. Of ther-
apeutic relevance, stimulating autophagy with rapa-
mycin and various mTOR-independent autophagy
inducers, such as carbamazepine, trehalose, ver-
apamil, and BRD5631, restored autophagic flux and
improved cell viability in NPC1 hiPSC-derived
neurons; however, only rapamycin and carbamaze-
pine were effective in NPC1 hiPSC-derived hepatic
cells [454,456]. The autophagy inducers were
cytoprotective on their own without co-treatment of
any cholesterol-lowering agents. In addition, recom-
binant VEGF treatment imparted similar beneficial
effects in NPC1 neurons [450]. Interestingly, while
the cholesterol-lowering agent, 2-hydroxypropyl-b-
cyclodextrin (HPbCD), further augmented the autop-
hagic block that could be detrimental [449,454,457],
the HPbCD analogue called methyl-b-cyclodextrin
(MbCD) improved the defective autophagic flux in
NPC1 hiPSC-derived neurons [455].
In a nutshell, a block in autophagic flux due to
impaired autophagosome maturation is a consistent
phenotype across various NPC1 disease models,
including iPSC-derived neurons where autophagy
inducers rescued the autophagy defect and
improved neuronal survival. However, further stu-
dies in Npc1 mutant mice are necessary to examine
the in vivo efficacy of autophagy induction and a
combination treatment strategy with cholesterol
depletion.
Spinocerebellar ataxias
Spinocerebellar ataxias (SCAs) are a group of
genetic, progressive neurodegenerative diseases
associated with loss of coordination of gait and
muscle movements. Impairment in autophagy has
been reported in some of the SCAs associated with
polyglutamine (CAG)-expanded aggregation-prone
proteins. These include SCA3 (MachadoeJoseph
disease) and SCA7 that are caused by the expan-
sion of the polyglutamine tract in ataxin-3 and ataxin-
7, respectively, and thus, are also known as
polyglutamine or trinucleotide repeat disorders
[396,458]. The polyglutamine domain of the wild-
type ataxin-3 was found to interact with the pro-
autophagic protein Beclin 1, whereby the deubiqui-tinase activity of ataxin-3 prevented the proteasomal
degradation of Beclin 1 to facilitate autophagy; an
effect that was suppressed by polyglutamine-
expanded mutant ataxin-3 or huntingtin [459].
Indeed, decreased levels of Beclin 1 were found in
SCA3 transgenic mice and patient fibroblasts
[459e461], whereas overexpression of Beclin 1
improved autophagic flux and exerted neuroprotec-
tive effects in SCA3 rat neuronal cultures [460]. In
addition, the reduction in sirtuin-1, which deacety-
lates autophagy proteins to induce autophagy
[462,463], was seen in the SCA3 mouse model
[464]. These effects were associated with inhibition
of autophagosome formation in SCA3 [459,461].
Likewise, the levels of autophagy-associated pro-
teins, Beclin 1, Atg7, Atg12, and Atg16, were
reduced in the brain of the SCA7 mouse model
[465]. Similar to the protective effects of autophagy
activation in other polyglutamine disorders like HD
via enhancing the clearance of aggregation-prone
proteins, autophagy inducers were also beneficial in
multiple in vivo SCA3 models. These include CCI-
779 (temsirolimus) in SCA3 mice [466], calpeptin
(calpain inhibitor) in SCA3 zebrafish [467], and
lithium chloride and sodium valproate in SCA3
Drosophila models [468,469].
A study with SCA3 patient-derived hiPSC model
confirmed that the autophagic flux was impaired in
hiPSC-derived neuronal cells, as evidenced by the
accumulation of p62 [470]. In these SCA3 neurally
differentiated cells, rapamycin-induced autophagy to
promote the clearance of mutant ataxin-3 without
any significant effects on its wild-type counterpart
[470]. Autophagy and lysosomal impairment were
also suggested in SCA14 hiPSCs, although these
cells were not differentiated into neurons [471].
Overall, although dysfunctional autophagy has
been reported in animal and hiPSC models of
SCA3, where autophagy induction is cytoprotective,
more studies are required to investigate the role of
autophagy in other SCAs.
Spinal bulbar muscular atrophy
Spinal bulbar muscular atrophy (SBMA, also
known as Kennedy disease) is an X-linked neuro-
degenerative inherited disease caused by the
expansion of polyglutamine (CAG) repeat in the
gene encoding for androgen receptor (AR). SBMA is
characterized by motor neuron loss in the brainstem
and spinal cord and is associated with muscle
weakness, atrophy, and endocrine manifestations
[472]. Proteasomal and autophagic dysfunctions
have been reported in SBMA [473]. Wild-type AR
was shown to interact with and act as a coactivator of
TFEB, whereas mutant AR prevented TFEB trans-
activation and downregulated its target genes in
mouse embryonic motor neurons stably expressing
mutant AR [474]. This effect was suggested to be
2781causing dysfunctional autophagic flux associated
with the accumulation of autophagosomes in these
mutant cells, as well as in motor neurons of
symptomatic SBMA mice (YAC AR100) [474].
Autophagic flux was also possibly retarded in the
skeletal muscle of SBMA mice (AR113Q knock-in)
and in mouse immortalized motor neuron-like cell
line, where autophagosomes, insoluble and aggre-
gated p62, and ubiquitinated proteins were elevated
[475,476]. However, in inducible PC12 cells expres-
sing mutant AR, autophagic flux was shown to be
increased via inhibition of the mTOR pathway along
with higher nuclear TFEB and cytoplasmic translo-
cation of the repressor ZKSCAN3 [475]. Likewise,
TFEB target genes are upregulated in skeletal
muscle biopsies of SBMA patients [475]. One
plausible explanation of these contrasting results
could be due to the cell type specificity. Despite
alterations in autophagy, mutant AR and the
associated aggresomes could be selectively tar-
geted for autophagic degradation mediated via the
HSPB8 (heat shock protein B8) and BAG3 (Bcl-2-
associated athanogene 3) complex [476e478].
HDAC6 (histone deacetylase 6) plays a role in
microtubule-assisted delivery of the lysosomes and
aggregated proteins, including mutant AR, to the
microtubule organizing center (MTOC), where it
enables autophagosome maturation and cargo
clearance [479e481]. Enhancing autophagy for
facilitating the clearance of mutant AR was cytopro-
tective in primary motor neurons from SBMA mice
and immortalized motor neuron-like mouse cell lines,
as seen with trehalose [476,482,483], phenoxazine
(AKT inhibitor) [482] and 17-AAG (HSP90 inhibitor)
[484], as well as with trehalose in immortalized
mouse myoblasts [485] and HDAC6 overexpression
in SBMA Drosophila model [479].
Autophagic defects have been suggested in
patient-derived hiPSC models of SBMA. Accumula-
tion of autophagosomes without an increase in
autolysosomes, reduction in the expression of
TFEB target genes, and mitochondrial depolariza-
tion were observed in neuronal precursor cells
differentiated from different SBMA hiPSC lines that
also exhibited buildup of insoluble mutant AR [474].
In these mutant cells, TFEB overexpression
improved autophagosome flux and mitochondrial
membrane potential [474]. Furthermore, increased
a-tubulin acetylation, reduced HDAC6 activity, and
decreased lysosomal enrichment around MTOC, all
of which could impact autophagy, were seen in
SBMA hiPSC-derived motor neurons [486]. Another
study using these SBMA motor neurons only
measured the mRNA levels of autophagy-related
genes, and thus, any changes in autophagy could
not be assessed [487]. None of these studies,
however, have robustly evaluated autophagic flux
in hiPSC-derived neurons, and therefore, robust
characterization is required to determine the extentand nature of autophagic dysfunction in these
disease-affected cellular platforms.
Charcot-Marie-Tooth disease
Charcot-Marie-Tooth (CMT) disease is an inher-
ited peripheral neuropathy, which affects motor and
sensory neurons and is associated with atrophy and
weakness in the distal extremities. There are two
types of CMT as per electrophysiological criteria:
CMT type 1 (CMT1) is the demyelinating form,
whereas CMT2 is the axonal form [488]. Although
there are multiple CMT-associated genes, mutations
inMFN2 cause CMT2A [489]. This gene encodes for
mitofusin 2, a GTPase located on the outer
membrane of the mitochondria regulating mitochon-
drial network homeostasis by mediating mitochon-
drial fusion, as well as mitophagy [490]. During
mitochondrial damage, PINK1-phosphorylated mito-
fusin 2 recruits parkin, which, in turn, ubiquitinates
mitofusin 2 that acts as a signal to initiate mitophagy,
whereas depletion of MFN2 impaired this process
[490e492].
On the contrary, a study with CMT2A hiPSCmodel
reported opposite results. Motor neurons generated
from CMT patient-derived hiPSC lines carrying
MFN2(A383V) mutation displayed increased autopha-
gic flux accompanied with a reduction in mitochon-
drial content, although mitochondrial distribution was
altered as seen clustering around the nucleus and
the axonal movement of mitochondria was slower
[493]. It is plausible that this mutation in mitofusin 2
may act via a gain-of-function mechanism that is
distinct from the knockdown or knockout effects with
mitofusin 2, and also the mutant protein may favor
mitophagy by altering mitochondrial localization.
Further confirmation of the impact on autophagy
and mitophagy processes may come from future
studies involving multiple hiPSC models, as well as
any therapeutic benefits of autophagy stimulation in
this condition.Concluding Remarks
Autophagy is essential for neuronal health, and
deregulation of this vital homeostatic process con-
tributes to neurodegeneration. While impairment in
autophagy has been reported in almost all the
neurodegenerative disorders studies, the nature of
the autophagic defects is sometimes different
between nonhiPSC and hiPSC-based experimental
systems (Fig. 5 and Table 2). The use of patient-
derived hiPSC models to generate disease-affected
cell types, such as neurons, may provide insights in
a manner relevant to human biology. These cellular
platforms are particularly important to evaluate the
therapeutic potential of autophagy inducers that
could be applicable to the patients (Table 3). Several
2782studies have been undertaken by utilizing hiPSC
models of various neurodegenerative disorders, as
described above (Table 1). However, further inves-
tigation is warranted in hiPSC-derived disease-
affected cell types of most diseases to precisely
characterize the nature of the autophagy dysregula-
tion, elucidate the underlying mechanisms causing
the autophagy defects, and assess the therapeutic
benefits with established autophagy inducers as a
proof-of-principle concept to understand whether
induction of autophagy is beneficial to the specific
disease-relevant contexts.
The promise of hiPSCs in disease modeling and
drug discovery is vast, with significant advances
being made in recent years. The ability to create
human patient-derived model systems is an oppor-
tunity not only in understanding disease mechan-
isms like autophagy as discussed above but also in
drug screening and facilitating patient-specific treat-
ment. On the horizon, there is also an autologous
hiPSC-derived cell transplant for the treatment of
disease [494,495]. Although there are considerable
challenges still to be overcome, global initiatives,
such as the establishment of international hiPSC
repositories for various diseases, developing novel
ways to induce cellular aging, refinement of hPSC
differentiation techniques and development of
increasingly complex three-dimensional and chi-
meric disease model systems are valuable in
furthering the extensive benefits to be derived from
hiPSC disease modeling.Acknowledgements
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